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1. Summary 
 
Dendritic cells can present exogenous antigen to CD8 T cells using a mechanism termed cross-
presentation. This mechanism is important for immune responses against tumors, viruses, 
intracellular pathogens and autoantigens expressed in peripheral tissues. However, the 
physiological mechanisms that regulate cross-presentation in vivo in particular the endocytosis 
mechanisms involved in this process are not well understood.  
The first aim of this study was to elucidate the role of the mannose receptor (MR), a C-type lectin 
in cross-presentation. MR deficient mice showed reduced uptake of soluble OVA and diminished 
activation of CD8 T cells. This was due to the reduced cross-presentation ability of DCs in MR 
deficient mice, as the MR was only present in the cross-presenting CD8α+ DCs. As opposed to 
soluble OVA, the cell-associated form of this model antigen did not use the MR to enter the cross-
presentation pathways. These data provide first formal evidences that a particular antigen uptake 
receptor, here the MR can specifically introduce antigen into the cross-presentation pathway. 
Furthermore, they identify this receptor as a further marker of cross-presenting DCs. 
The second aim of the present study was to identify the mechanisms by which soluble antigens are 
transported from the peripheral organs to draining LNs for subsequent cross-presentation. Proteins 
smaller than the molecular weight of albumin, such as soluble OVA theoretically may pass the 
kidney glomerular filter and be concentrated in the tubular compartment. It appeared possible that 
this physiological process might increase the availability of antigen for the cross-presenting APC. 
Therefore the kidney - renal lymph node (rLN) system was choosen to investigate antigen 
transport from organ to draining LN. Several lines of independent evidence indicated that soluble 
OVA was concentrated in the kidney DCs but was transported in a cell-independent fashion to DC 
resident in the rLN. Further studies showed that these DCs tolerized specific T cells. This 
tolerization was independent from steady-state migration of kidney DC to draining LN. These 
findings identify the rLN as a unique site where antigen is rapidly enriched for T cell activation; 
provided it is small enough to pass the glomerular filter. This mechanism may contribute avoiding 
unwanted immune responses against innocuous circulating antigens, for example self-serum or 
food proteins. 
In conclusion the present study revealed new in vivo mechanisms in regulating cross-presentation 
of soluble molecules such as antigen uptake via MR and antigen presentation occurring in the 
kidney – renal LN system. 
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3. Abbreviations 
 
AICD  Activation induced cell death 
aOVA  Alexa647-labeled Ovalbumin 
APC  Antigen Presenting Cell 
BM  Bone marrow  
BM-DC Bone marrow derived dendritic cells 
BSA  Bovine Serum Albumin 
CCL  Chemokine Ligand 
CCR  Chemokine Receptor 
CFSE  5,6-Carboxy-Succinimidyl-Fluoresceine-Ester 
cLN  Cutaneous lymph node 
CLR  C-type lectin receptor 
CRD  Carbohydrate recognition domain 
CTLA-4 Cytotoxic T-lymphocyte antigen-4 
DC(s)  Dendritic cell(s) 
DCIR2  Dendritic Cell Inhibitory Receptor-2 
DC-SIGN Dendritic-cells specific ICAM-3 grabbing non-integrin 
DTR  Diphteria Toxin Receptor 
EDTA  Ethylene-diamin-tetraacetate 
FITC  Fluorescein-5-isothiocyanate 
FRC  Fibroblastic reticular cells 
GMB  Glomerular basal membran 
HEV  High endothelial venules 
HSP  Heat shock protein 
ICAM  Intracellular Adhesion Molecule 
IL  Interleukin 
ITAM  Immunoreceptor tyrosin-based activation motif 
ITIM  Immunoreceptor tyrosin-based inhibitory motif 
i.v.  Intravenous 
JAM  Junctional adhesion molecule 
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kDC  Kidney dendritic cells 
LN(s)  Lymph node(s) 
LPS  Lipopolysaccharide 
MACS  Magnetic Cell Separation 
MFI  Mean fluorescence intensity 
MHC I-II Major Histocompatibility Complex-I-II 
MR  Macrophage Mannose Receptor 
NK  Natural killer cells 
NKT  Natural killer T cells 
NX  Nephrectomy 
OVA   Ovalbumin 
OVA-CFA Ovalbumin in complete Freund`s adjuvant 
PD-1  Programmed death receptor-1 
PFA  Paraformaldehyde 
PS  Phsophatidyl serin 
RAG  Recombination activating gene 
rLN  Renal lymph node 
s.c.  Subcutaneous 
sMR  Soluble Macrophage Mannose Receptor 
TLR  Toll Like Receptor 
TNF  Tumor Necrosis Factor 
7AAD  7-aminoactinomycin D 
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4. Introduction 
 
4.1 The immune response 
 
Two major types of lymphoid tissue are relevant for induction of adaptive immunity: primary 
lymphoid organs like the thymus which is responsible for generation of T cells from 
precursors and secondary lymphoid organs such as the spleen, lymph nodes (LNs) and Peyer`s 
patches, which represent sites of immune induction. Naïve T cells simply recirculate between 
the different secondary lymphoid compartments, continually examining antigen-presenting 
cells (APC) for the presence of their cognate ligand. Recognition of cognate ligand leads to the 
activation, proliferation and differentiation of T cells into effector and memory cells. The 
effector cells after leaving the LNs are capable of entering peripheral tissues and targeting site 
of inflammation in order to fulfill their immune function (1). 
 
 
4.2 Dendritic cells 
 
The dominant APC in the body are the dendritic cells (DC). In the mouse, these cells are 
characterized by the expression of the integrin CD11c. Under steady state conditions, 
phenotypically immature DCs can be found in peripheral tissues and in secondary lymphoid 
organs (2). In this state they are highly phagocytic and express low level of MHC II and 
costimulatory molecules such as CD80, CD86 (3). Upon maturation with different stimuli; 
such as TLR ligands, inflammatory cytokines or CD40-signals after interaction with T cells; 
they decrease their antigen uptake capacity and upregulate MHC I, MHC II, CD80, CD86 and 
can produce proinflammatory mediators like IL-12, TNF-α and IL-6, in order to initiate T cell 
responses (3, 4). DCs, dependent on their maturation state, surface molecule expression, and 
their cytokine secretion profile, can dictate the type of immune response they induce. Thus, 
they can decide whether to promote T helper or regulatory T-cell responses (5, 6). 
Furthermore, DCs present also antigens against which not immunity but tolerance is induced. 
These antigens include environmental proteins chronically found for example in the 
respiratory tracts (7, 8) as well as self-antigens derived from different organs (9-12). Capture 
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of these antigens under steady state conditions, in the absence of microbial or inflammatory 
stimuli, allows DCs to control tolerance (13). In addition to their role in adaptive responses, 
DCs play a critical role in innate immunity. They are active in responding to microbial 
challenge and can produce numerous different cytokines involved in host defense, such as IL-
12 and both type-I and type-II interferons (6). DCs also can activate NK and NKT cells, which 
are innate lymphocytes that rapidly kill selected targets and produce different cytokines (14, 
15).  
Dendritic cells are heterogeneous and can be divided into at least six subsets in mice (16-19). 
Properties of the different subsets are summarized in Fig. 1. 
 
 
Figure. 1 Mouse DC subsets, surface phenotype and some important properties 
(Adapted from Heath WR. et al. 2004 Immun. Rev. (19)) 
 
 
The DC subsets are usually separated by their surface receptor expression. DC expressing 
distinct subset markers are thought to represent distinct cell lineages that are not 
interconvertable (20). Recently, Shortman et al. (17) distinguished three categories differing in 
functionality and lifetime location: Pre-DCs, inflammatory DCs, and conventional DCs. 
Dependent on the migratory ability, later differentiation stages were further divided into 
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lymphoid tissue resident and classical-migratory DC. The impact and regulation of DC 
migration are discussed below in details. 
 
 
4.2.1 Dendritic cells are especially abundant in the kidney 
 
The kidney tubulointerstitium contains numerous dendritic cells, whose function is largely 
unresolved (21, 22). They are located adjacent to the basolateral surface of the tubular 
epithelium and the peritubular capillaries (21). As was described by Dong et al. they could 
acquire iv. injected dextran molecules from the blood and from the ultrafiltrate as well (23). 
However the functional consequence of this later phenomenon is unclear. Murine kDC were 
characterized by CD11c, MHC II, F4/80 and CD11b expression, were phenotypically 
immature and elicited weak allogenic T cell responses (21). In vitro study further 
demonstrated that kidney DCs, isolated from Flt3 treated animal, could promote the generation 
of CD25+CD4+IL10+ regulatory T cells (24). The tolerogenic phenotype of kDCs was 
additionally investigated in allograft rejection where transfer of freshly isolated kDCs 
prolonged heart allograft survival (24). Due to the low number of functional studies available, 
the exact role of these cells is in the kidney under physiological and pathological condition is 
unknown. 
In mouse models, autoantigen, expressed in the kidney, are presented in draining LN and 
induce T cell tolerance (11, 25), however it is unknown how these antigens reach the kidney 
draining LN. It has been shown that freshly prepared kDCs expressed CCR1, CCR2, CCR5, 
CX3CR1 and very low levels of CCR7 (22, 26). LPS stimulation in vitro resulted in 
upregulation of CCR7 (26), suggesting that kDCs may use this chemokine receptor to leave 
the kidney under inflammatory condition or after maturation.  The exact role of chemokine 
receptors in DC migration in vivo needs to be further elucidated. 
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4.2.1.1 Filtration as a physiological role of the kidney and its filtration 
barrier 
 
One of the central functions of the kidney is to excrete low molecular weight plasma waste 
products into the urine while ensuring that useful filtrated molecules are reabsorbed. The 
filtration of plasma occurs in specialized filtration units called glomeruli. The glomerulus 
contains a capillary network, which is surrounded by the Bowman’s capsule that collects the 
filtrated primary urine and introduces it into the tubular system (Fig. 2 A, B). The glomerular 
capillary wall forms a filtration barrier, which consists of three layers: the inner fenestrated 
vascular endothelium, the glomerular basement membrane (GBM) and the podocyte cell layer. 
Between the foot processes of podocytes a porous filter is formed, the so called slit-diaphragm 
(27) (Fig. 2 A, B). This barrier allows free filtration of molecules below of 70 kDa and ensures 
that cells and molecules above this size are retained in the circulation. In addition to the size 
the discrimination is based on 3D structure and the charge of the molecules, allowing a greater 
penetration of neutral and cationic molecules than of anionic ones of the same size (28). The 
damage of this barrier, as seen in several inherited or acquired diseases, results in proteinuria, 
which leads to severe glomerulopathies with end-stage renal disease as a final consequence 
(27). 
 
Figure 2. The structure of the filtration barrier of the kidney 
A The anatomical structure of the glomeruli.  
B The area signed green in A is enlarged. The different layers involved in formation of the      
        filtration barrier are shown: podocytes, basal lamina, and fenestrated endothelium. 
 (Adapted from Berne & Levy Principles of Physiology, (29)) 
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4.2.1.2 The fate of filtrated proteins – the albumin retrieval pathway 
 
Approximately 60 % of the total plasma protein in the serum is albumin. The molecular size of 
68 kDa results in filtration of this molecule (30). Therefore albumin has been extensively 
studied as a model for filterable proteins, in order to follow the fate of such molecules in the 
kidney. In spite of the daily filtrated load of albumin, which can reach as much as 8 g/day in 
humans, there are only small amount of this molecule (30mg/day) found in the urine, 
suggesting more than 99 % of reabsorbtion (30, 31). Reabsorbtion takes place via receptor-
mediated endocytosis by the proximal tubular epithelial cells. The reabsorbed albumin 
undergoes lysosomal degradation into small peptides within minutes in humans and rats which 
are subsequently released from the basolateral side of the tubular epithelium into the blood 
stream (28, 31). Understanding the fate and consequence of filtrated molecules in the kidney 
on the cellular level is especially important since several studies underlined that both under 
physiological and pathological conditions, albumin (32-34) as well as other filtrated proteins 
such as growth factors (35) can induce functional responses in kidney tubular cells such as 
certain chemokine expression which can contribute renal pathology and disease progression. 
The influences of these events on cellular functions of neighboring non-tubular cells, and the 
immunological consequences of these processes in healthy and disease animals are largely 
unresolved.  
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4.3 Cross-presentation, cross-priming and cross-tolerance 
 
Naive CD8+ T cells recognize antigens in context of major histocompatibility complex-I 
(MHC I) molecules. Two pathways have been reported to enable DC to process antigens into 
this pathway for activation of naïve CD8+ T cells. The first is the classical pathway: it 
constitutively facilitates processing of antigens synthesized within the cells for loading on 
MHC I molecules. The second pathway allows DCs to internalize antigen from the 
extracellular environment and present them as MHC I bound peptides. In 1976 Bevan et al. 
(36) described this phenomenon for the first time. He immunized mice with allogenic cells and 
examined the MHC restriction of the induced CTL (cytotoxicity T cell) response. Such 
immunization generated minor histocompatibility antigen specific CTL that were restricted to 
both donor and surprisingly host MHC I molecules. The latter was only possible if the host 
cells acquired donor cellular antigens and processed them on MHC I to induce CTL. This 
process has been termed as cross-priming. The underlying antigen presentation event has later 
been termed cross-presentation. The induction of CD8+ T cell immunity is now generally 
termed cross-priming whereas the induction of CD8+ T cell tolerance is called cross-
tolerance. 
 
 
4.3.1 What are the cross-presenting APCs? 
 
4.3.1.1 Dendritic cells 
 
Dendritic cells (DC) have been described to be particularly capable of cross-presentation (37-
40). For example, this has been shown by isolating DCs from animals injected with various 
form of antigen and determining ex vivo their ability to induce CD8 T cell responses (37-39, 
41, 42). Also it has been shown that DCs exposed to antigen in vitro stimulated CD8 T cells 
upon injection into recipient mice whose resident DCs were incapable of presenting the 
antigen (43). A further approach is the generation of bone marrow chimeras where only host 
DCs can present the antigen to CD8+ T cells (44, 45). Microscopy studies showed that during 
viral infection, proliferating CD8 T cells clustered with cross-presenting DCs within LNs (46). 
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In spite of this, an important reciprocal experiment; proving the importance of DCs in cross 
presentation; was made by Jung et al. using CD11c-DTR mice where in vivo depletion of DCs 
inhibited induction of efficient CTL against cell associated antigen (47). However, it has to be 
kept in mind that some macrophages were also depleted in these mice (48). 
 
 
4.3.1.2 DC subtypes with distinct ability for cross-presentation? 
 
The first study that addressed which DC subset mediates cross-presentation of cellular antigen 
came from den Haan et al. (37), who identified that CD8+ DC as responsible for cross-priming 
CTL immunity to OVA-loaded spleen cells. This finding was corroborated by others showing 
that CD4+ T cells responding to OVA-loaded spleen cells also recognized antigen on the CD8+ 
cross-presenting DC (40, 49). Furthermore, antigen presentation to CD4+ T and CD8+ T cells 
by the same DC was required to induce CD4 help ("cognate help") (50). This allows the CD4+ 
T cell using CD40L to stimulate DCs, which is necessary to induce efficient effector and 
memory CD8+ T cell responses (51-54). Above data were consistent with the finding that only 
CD8α+ CD205+ DCs were able to capture apoptotic cell material in the spleen (40, 55). 
However soluble antigen was shown to be taken up by both CD8+ and CD8- DC while only the 
CD8+ ones could cross-present (39, 56). In contrast to this, under certain conditions; such as 
TLR stimuli (39) or in case of immuncomplexes (38) and peripheral tissue expressed 
autoantigens (10, 21, 57) cross-priming or cross-tolerance can be induced by not only CD8+ 
but also by CD8a- DCs. 
 
 
4.3.1.3 Macrophages and other cells with cross-presenting abilities 
 
Although DCs are considered the APC most capable of cross-presentation, other cells can also 
perform this function. For example, macrophages presented antigens on MHC I in vitro (58-
61) and in adoptive transfer model peptide loaded macrophages are capable of migrating to the 
draining LN and there directly activating CD8+ T cells (43). However, op/op mice (62) and 
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mice depleted of macrophages by using toxic liposome (63) did not exhibit substantial defect 
in initiating adaptive T cell responses. 
Other cell types also have been reported to cross-present including B cells (64, 65), human γδ-
T cells (66), neutrophils (67, 68) and liver sinusoidal endothelial cells (69). The latter cell type 
in the liver could cross-present food antigens and induce cross-tolerance (70). 
 
 
4.3.2 What types of antigens are cross-presented? 
 
Since cross-presentation was discovered there are tremendous evidences for its importance in 
CD8 T cell responses against tumors, viruses, parasites, intracellular bacteria and autoantigens 
expressed in peripheral tissues (19, 71, 72). Various forms of antigen can be cross-presented 
such as soluble proteins, HSP-peptide complexes, immuncomplexes (3, 4). In general cross-
priming is biased towards high dose antigens (73) with long half-life (74), and towards cell 
associated antigens (75), and antigens released during cellular destruction (73). In the case of 
cross-presentation of cell associated antigen the exact form of antigen transferred from donor 
cells to the cross-presenting APC is not exactly known. Cross-presentation does not require 
proteosome activity in the antigen carrying cells (76-78) and as relevant substrate proteolytic 
intermediates of the proteosome rather than fully processed peptides are considered. This is 
consistent with studies where expression of the minimal peptides as minigenes in the donor 
cells did not result in cross-presentation (78, 79). However, under certain in vitro conditions 
peptide transfer through gap junctions from the donor cells to the cross-presenting APC has 
been described (80).  
 
 
 15
4.4 Physiological processes regulating availability of antigens for the cross-
presenting APC 
 
 
4.4.1 Antigen uptake 
 
Distinct endocytotic pathways exist to allow internalization of different molecules from the 
extracellular milieu. APCs like DC use similar pathways found in other cells such as 
phagocytosis, macropinocytosis, and receptor mediated endocytosis (4).  
 
 
4.4.1.1 Phagocytosis, macropinocytosis 
 
Particles and soluble antigens are efficiently internalized by phagocytosis and 
macropinocytosis, respectively. Both processes need actin assembly and formation of 
pseudopod resulting in the formation of large intracellular vacuoles (81, 82). Phagocytosis 
denotes the ingestion of large particles or cells > 1µm in diameter and is usually receptor 
mediated (81). Immature DCs were described to phagocytose bacteria, fungi, and different 
parasites (3). In the gut epithelium immature DCs projected their dendrites to the apical site of 
the epithelia and phagocytose bacteria from the intestinal lumen (83). Furthermore DCs 
phagocytosed apoptotic or necrotic cells, inert particles or liposomes (4) and they could also 
“bite” pieces of from living neighboring cells in the process termed nibbling (3, 84). In 
phagocytosis of apoptotic cells αVβ5, αVβ3 integrins (85), complement receptor (CR3) (86), 
and scavenger receptors like CD36 (87) and PS (phosphatidyl serine) receptor (88) have been 
implicated. However in DCs no single receptor has been unequivocally proven to be 
responsible, suggesting they employ parallel or redundant phagocytic receptor systems for the 
uptake of apoptotic cells, as shown in various knock-out models (89-91).  
Macropinocytosis is formed almost exclusively at sites of membrane ruffling, and there is no 
evidence prooving that receptors are involved (82). This membrane ruffling mechanism is in 
DCs at least partially regulated by Cdc42-Rac interaction (92, 93) and can be transiently 
upregulated after TLR stimulation in the early phase of DC maturation (94). In human 
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monocytes-derived immature DCs, constitutive activity of this process has been proposed, 
which could reach a rate as high as 40 % of the volume of the cell every hour (95). 
Macropinocytosis allows cells to internalize large amount of extracellular fluid and fluid 
dissolved antigen. It has been shown to convey antigens to the MHC II pathway, furthermore 
under certain in vitro conditions it could lead antigen also to the cross-presentation pathway 
possibly via allowing access of internalized antigen to the cytosol (96). Nevertheless direct 
intracellular evidence for such transport via macropinocytosis to the MHC I pathway is still 
absent. Furthermore, an involvement of this process in vivo in the induction of T cell 
responses remains to be shown. 
 
 
4.4.1.2 Receptor mediated endocytosis 
 
Receptor mediated endocytosis allows the uptake of macromolecules through specialized 
regions of the plasma membrane called coated-pits. This process in general initiated by a 
signal in the cytoplasmic tail of the receptor and leads typically to the formation of clathrin-
coated endocytic vesicles (81). To a lesser extent caveolin-coated vesicles can be formed but 
evidence is scarce that DC use this mechanism extensively (4). Furthermore, DCs can exhibit 
also a further form of endocytosis that involves neither clathrin nor caveolin (4). Proteins 
internalized by any of these mechanisms eventually reach the endosomal/ lysosomal 
compartments, and are loaded on MHC II (4). Many of these receptors; such as Fc- (38, 97), 
Hsp receptor CD91 (98), complement- (3), scavenger-receptors (99) and members of the C 
type-lectin family such as DEC205 (13, 100) have been reported to shuttle antigens also into 
the cross-presentation pathway. 
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4.4.1.3 C-type lectins 
 
 
 
Figure 3. The type-I and type II C-type lectin receptors expressed on dendritic cells 
C-type lectins (MMR and DEC-205) contain an amino- terminal cystein-rich repeat (S–S), a 
fibronectin type II repeat (FN) and 8–10 carbohydrate recognition domains (CRDs), which bind ligand 
in a Ca2+-dependent manner. Type II C-type lectins contain only one CRD at their carboxyl-terminal 
extracellular domain. The cytoplasmic domains of the C-type lectins are diverse and contain several 
conserved motifs involved in antigen uptake: a tyrosine-containing coated-pit intracellular targeting 
motif, a triad of acidic amino acids and a dileucine motif. Other type II C- type lectins contain potential 
signaling motifs (ITIM, ITAM, proline-rich regions (P)).  
CLEC-1, C-type lectin receptor 1; DCIR, dendritic cell immunoreceptor; DC-SIGN, dendritic-cell 
specific ICAM-3 grabbing non-integrin; DLEC, dendritic cell lectin; ITAM, immunoreceptor tyrosine-
based activation motif; ITIM, immunoreceptor tyrosine-based inhibitory motif; MMR, macrophage 
mannose Adapted from Figdor CC. 2004 (101) 
 
 
For antigen recognition DCs rely on cell surface receptors to recognize between harmless self-
antigens and pathogen-derived antigens. DCs express an array of pattern recognition receptors 
such as C-type lectin receptors (CLR) and Toll like receptors (TLR) (102). Both are involved 
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in innate and adaptive immune responses. The term CLR defines carbohydrate-binding 
molecules that bind ligands in a Ca2+-dependent manner. Type I receptors contains 
extracellularly multiple, type II only one of the carbohydrate recognition domain (CRD) (Fig. 
3.). 
Using CRD domains, some CLRs recognize N-linked and others O-linked glycosylation sites. 
Latter structures are often exposed on collagens, mucins and some pathogens whereas N-
linked structures are present on the vast majority of glycoproteins in the body as well as on 
pathogens that use the host’s glycosylation for their survival or spread such as retroviruses 
(102, 103). Although some CLRs recognize monosacharides, like mannose, fucose or 
galactose, studies showed that the receptor specificity depended on their exact counter 
structure differing in carbohydrate branching, spacing creating unique sets of carbohydrate 
recognition profiles. (102, 104, 105) Most CLR receptors function as antigen receptors that are 
involved in recognition of different pathogens such as bacteria, parasites, fungi and viruses 
(105, 106). In addition to the role in pathogen recognition under steady state conditions, CLRs 
are important in the clearance of self-antigen and the induction of tolerance (102). Antigen 
targeting of CLRs such as DEC-205 in vitro and in vivo leads to CD8+ T cell tolerance and 
induction of Tregs (100, 107). The endocytosis mediated by CLRs is guided by their 
intracellular internalization motifs, whereas some of them contain also ITAM, ITIM  (Fig. 3) 
suggesting potential involvement in signal transduction thereby regulating cellular functions 
(101). Evidence is emerging that they can also synergize or antagonize TLR signaling like in 
case of mycobacterial products recognized by DC-SIGN, which induces IL-10, and favors 
immune escape, antagonizing TLR mediated IL-12 production in DCs (108, 109). In addition 
to self and non-self antigen recognition, CLRs are important in mediating cell adhesion, 
homing of leukocytes and even have been shown to provide costimulation during T cell 
responses (102, 110).  
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4.4.1.4 The Mannose receptor 
 
The MR family includes MR itself as well as Endo-180, DEC-205 and the phospholipase A2 
receptor. Mannose receptor (MR) is one of the best-characterized type-II CLR. A wilde range 
of bacteria, yeast and viruses have been described to be recognized by MR (111). (Fig. 4 B) 
On the molecular level, the receptor recognizes ligands bearing mannose, fucose, N-acetyl 
glucosamin mediated by its CRDs. (Fig. 4 A) Additionally, via the cystein rich domain, it can 
bind to sialoadhesin and sulphated carbohydrates (112, 113). 
 
 
Figure 4. The structure and binding properties of the MR 
A The extracellular domain structure of MR included ligands for each of the binding regions 
B The MR binds multiple self and non-self ligands through both cystein rich and carbohydrate          
              recognition domain. List of ligands are shown. Modified based on Taylor PR. et al. (111)  
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MR-/- mice, generated by two separate groups (114, 115), allowed determining the 
requirement of the MR for detecting ligands that had been identified in vitro. Surprisingly 
these mice showed no increased susceptibility to infection against Candida or Pneumocystis 
carinii (116, 117). Instead, these mice had increased plasma levels of endogenous proteins 
such as lysosomal hydrolyses (114) and a defect in clearance of luteotropin, latter responsible 
for reduced litter size in these animals. Additionally, the MR was involved in the clearance of 
potentially harmful endogenous inflammatory glycoproteins like lysosomal acid phosphatase 
(118) or the neutrophil derived myeloperoxidase (119). These phenotypes revealed a 
functional redundancy between CLRs in vivo and highlighted the difficulties to predict MR 
contribution in host defense from in vitro ligand binding studies.  
In spite of the numerous ligands identified for MR it functions not only as a simple scavenger 
receptor but also could mediate cell adhesion of lymphocytes through L-selectin (120). 
So far most studies have addressed the function of the MR in macrophages, where it is 
expressed most abundantly (101). In addition to this, MR has also been detected in liver 
endothelial cells, dermal microvascular endothelial cells, monocytes, Langerhans cells and 
dendritic cells (101). 
 
 
4.4.1.5 MR and antigen presentation in DC 
 
The MR has been described as a broad specificity antigen receptor in human monocytes-
derived DCs to concentrate macromolecules in MHC II compartment (95, 121). Further 
involvement in antigen presentation was reported in vitro by targeting the MR on human DC 
with mannosylated BSA or anti-MR mAb fused with tumor antigen, which led to 
internalization and presentation to T cells in the context of both MHC I and II (121, 122). 
Additionally mannosylated protein antigen resulted a 200-10.000-fold increase in antigen-
presentation of human DCs on MHC II compared to non-mannosylated ones (123). These in 
vitro findings encouraged some groups to designe vaccine using mannosylated tumor-antigens 
in order to induce anti-tumor responses (124, 125). Some of these vaccines are currently in 
clinical trial phase I (126). However, when interpreting these studies it has to be considered 
that mannan or mannosylated proteins which bind with high affinity to MR, also bind to other 
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C-type lectins such as DC-SIGN (127), that might also have contributed to antigen 
presentation. 
The subcellular localization of MR-internalized cargo revealed that it exclusively localized in 
early endosomes and was excluded from MHC II+ compartments (121, 123, 128). Others 
demonstrated colocalisation of the MR with MHCII+ CD1b+ vesicles, suggesting involvement 
also in glycolipid presentation (129). The majority of cellular MR was found within the 
endocytotic pathway and only 15-30 % of the cellular pool located on the cell surface (130). 
Thus, it was suggested that the MR functions as a fast uptake receptor facilitating rapid 
internalization of different glycosilated antigen, which can become available for processing 
and presentation. An unresolved question was the involvement of MR in cross-presentation 
and its effect on T cell activation in vivo. Direct evidence for these functions is limited and 
contraversial. First of all there is a disagreement on the expression of MR in vivo. In the 
murine system, it was not expressed in T cell areas of secondary lymphoid organs such as the 
spleen and LNs, which argued against an involvement of the MR in the induction of T cell 
responses (131). Besides the cell-associated form of the MR, some studies detected a soluble 
from of this receptor (sMR) in the supernatant of human DC cultures and in the murine serum 
(132). The functional relevance of this finding is unclear. In vivo studies using a construct 
containing the cystein rich domain of the MR fused with the Fc portion of human IgG 
identified MR ligands in vivo in marginal metallophillic macrophages of the murine spleen, in 
follicular DC and in subcapsular macrophages of the LNs (133). Although such interactions 
between MR+ cells or sMR targeted to CR-ligand-bearing cells suggested an influence on 
immune responses, formal evidence supporting this notion is scarce.  
Upon stimulation with OVA in Alum, CR+ cells in the spleen showed DC morphology, 
expressed CXCR5 surface marker and were able to enter the B cell follicles. In addition, after 
sorting, these cells could present antigen to T and B cells in vitro (134, 135). These findings 
suggested that MR+ cells might transport antigen to the places where adaptive immunity is 
induced. Alternatively, antigen bound to sMR could be targeted to CR+ cells, implying that the 
MR could connect innate and adaptive immunity.  
The cytoplasmic tail of the MR shows a lack of signaling motifs such as ITAM or ITIM, 
therefore it is not expected that antigen uptake would lead to DC activation or cytokine 
release. However, it has been reported that anti-MR antibodies or mycobacterial glycoproteins 
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matured human DC, resulted in IL10 production, and induced a regulatory phenotype in co-
cultured T cells (136, 137). Such anti-inflammatory effects were seen also with LPS, implying 
a possible cross talk between MR and TLR4 (137). Other ligands such as mannoprotein 
derived from Cryptococcus neoformans induced efficient IL-12 production and DC maturation 
in human DCs (138). The above findings raise the question whether the MR could be 
associated with different adapter molecules in order to alter cellular functions, but this 
possibility is speculative at present. 
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4.4.2 The lymphatics and the conduit system 
 
The lymphatic capillaries are blind-ending vessels located in various organs, consisting of 
endothelial cells and basement membrane. These capillaries converge to lymphatic vessels, 
surrounded by smooth muscle cells, facilitating an intrinsic pump activity of the vessel. This 
pump together with extrinsic factors such as a movement of surrounding tissue itself maintains 
the lymphatic flow. Additionally, valves can be found in bigger lymphatic vessels, which 
guarantee unidirectional flow. The transported lymph enters the draining LN from the afferent 
lymph vessel into the subcapsular sinus. (Fig. 5)  
 
 
Figure 5. The structure of the lymphatic conduit system 
Schematic diagram on the left shows the structural component of the lymph node. FRC conduit starts 
from the subcapsular sinus and drains lymph to the perivenular channel of the HEV. On the right side 
of the diagram it is shown how the FRCs envelop the reticular fibers forming channels for the 
lymphatic flow. Adaptation based on von Adrian et al. (139) 
 
 
From here most of the lymph is channeled through trabecular sinuses across the parenchyma 
towards the medulla and from there to an efferent lymphatic vessel, which finally leaves the 
LN (139, 140). Some of the lymph enters the intranodal lymphatic channels. These consist of 
fibroblastic reticular cells (FRCs) and network of reticular fibers. FRCs envelop these reticular 
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fibers, forming channels that project from the subcapsular sinus into the T cell area (Fig. 5). 
This, the so-called conduit system (139, 141), functions primarily as a size exclusion channel 
allowing small molecules such as chemokines, or injected tracers to reach the T cell zone, the 
perivenular channels and finally the HEV. Conduit systems as described above were found not 
only in LNs (141) but also in the thymus (142) and in the spleen (143). The function of this 
system is to transport chemokines, both homeostatic (CCL19, 21) (144, 145) and 
inflammatory such as CCL2 (146), arriving with the lymph from the periphery and further 
target them to the HEV. Thus, it is functioning as a remote control of the peripheral tissue for 
leukocyte recruitment to LN. This system however also allows efficient transport of soluble 
tracers or injected antigens arriving with the lymph flow into the T cell/DC zones (147-150). 
These molecules can accumulate in resident dendritic cells of the T cell area (150). Itano et al. 
have shown a physiological consequence of this system that antigen arriving into LN DC 
independently via the conduit induced functionally different CD4+ T cell responses compared 
to antigens carried by DC (149). In spite of studies using artificial settings, such as s.c. 
injection of high amount of tracers or antigens, (148-150) evidence is scarce that under 
physiological conditions such antigen transport occurs and how it might contribute to T cell 
responses. 
 
 
4.4.3 Migration of dendritic cells 
 
Current authoritative reviews distinguish two DC subtypes with distinct migratory properties 
inside the secondary lymphoid organs (17). One is lymphoid tissue resident non-migrating 
DCs, which exhibit immature phenotype. It can be further divided into CD8+ and CD8- DC 
subpopulations. They take up antigen arriving in the LN via the lymph or via migrating DC. In 
viral infection (151), migratory DC can hand over antigen to draining LN-resident DC for 
presentation to T cells, in order to induce immunity (57, 151). These organ derived migratory 
DC represent the other of the two groups of DCs: They sample antigen in peripheral tissues 
and transport it to draining LN in order to induce T cell response, either directly or indirectly 
by transferring antigen to LN-resident DC (17). Migration is triggered by microbial stimuli or 
by inflammatory cytokines (152). Evidence for such triggered migration has been presented in 
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the skin, the gut, and the lung (8, 153, 154). After exposure to inflammatory stimuli tissue 
DCs undergo maturation, and upregulate chemokine receptors such as CCR7, CXCR4, and 
CCR4 (155). The major chemokine receptor implicated in migration of DC to draining LNs is 
CCR7 (156). In CCR7 deficient mice DC migration from the skin, gut, and lung was reported 
to be severely impaired (8, 153, 154, 156). In order to reach the draining LN, DCs first have to 
enter the lymphatics possibly via adhesion molecules such as ICAM-1, JAM-1 (157). DCs 
migrate towards CCL21-leu and CCL19 expressed inside of the lymphatic vessels, resulting in 
their arrival in the subcapsular sinus of the draining LN (140, 157). There they are further 
directed towards the paracortex by CCL21-ser, CCL19 derived from stroma cells and the HEV 
in order to reach the place of the induction of T cell activation (140). Maturing DCs can also 
produce CCL19, which can induce signaling involved in rearrangement of the cytoskeleton 
(155, 158). Therefore it is possible that DCs use also autocrine mechanisms for CCR7-
dependent migration. However the expression of CCR7 alone is not sufficient for DC 
migration. Other signals such as lipid mediators, cysteinyl leukotriens, prostaglandin E2, and 
CD38 are required to sensitize CCR7 to its ligands CCL19 and CCL21 (157). Possibly these 
mediators alter intracellular signaling pathways, but the exact mechanisms are unclear.  
Additional factors independent from the CCR7 were also described to influence DC migration 
including SP1 (159), histamine, adenosine, and prostaglandin-D2 (157). The latter two are 
important in counterbalancing migratory properties of DCs (157).  
In the absence of inflammation, constitutive migration of immature DC to organ-draining LN 
has been observed, for example in the skin (153). Such "steady-state" DC migration is thought 
to mediate T cell tolerance against organ-derived antigens (13). Tolerogenic cross-presentation 
of antigen to CD8+T cells (cross-tolerance) has been shown to apply to pancreatic or kidney 
self antigen in the respective organ-draining LN (11). It is unresolved whether cross-tolerizing 
DCs were migratory or whether LN-resident CD8+ DC after capturing antigen from organ 
derived steady-state migrating ones mediated tolerance. In such steady state migration CCR7 
was also implicated (153). 
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4.5 The outcome of cross-presentation – tolerance vs. immunity 
 
Heamatopoetic T cell precursors migrate to the thymus where they undergo positive and 
negative selection based on their TCR interactions with MHC-peptide complexes, resulting in 
deletion of self-reactive T cells (Central tolerance). Despite of thymic tolerance, healthy 
individuals harbor self-reactive T cells in the periphery, but these are controlled by so-called 
peripheral tolerance mechanisms acting either directly on the self-reactive T cells (T cell 
intrinsic) or indirectly via additional cells (T cell extrinsic) such as T regulatory cells (160). 
One of the peripheral tolerance mechanisms is the so-called T cell ignorance, which denotes a 
situation where self-antigen is not accessible (160) or because the amount of antigen does not 
reach the required threshold (73) to trigger T cell response. Encountering self-antigen by T 
cells might alternatively lead to functional inactivation, termed anergy. Anergic T cells are 
characterized by the lack of cytokine production like IL-2, IFN-γ upon restimulation. It has 
been proposed that the lack of costimulation such as CD80, CD86 is responsible for the 
induction of T cell anergy (160). Later it became obvious that many other signals delivered 
through various receptors involving for example CTLA-4, PD-1 (161) contribute to this 
process (162, 163). Beside this, many signaling and adaptor molecules have been proposed to 
cause T cell unresponsiveness (164-167).  
When T cells become fully activated there are still opportunities to induce tolerance. One 
possibility is the phenotypic skewing when the nature of the response is directed to avoid the 
pathogenic effects like in case of polarization of T cell response towards TH-2 cells. Such TH-2 
responses have been linked with down regulation of autoimmunity in diabetes or EAE 
(Experimental Autoimmune Encephalitis) (160). Also regulation of chemokine receptor 
expression might serve to prevent autoimmunity in the periphery (168). 
Autoimmunity induced by fully activated T cells can be prevented by deletion of the given T 
cell clones via activation induced cell death (AICD). This mechanism was reported in many 
models where autoantigen was expressed in peripheral tissues such as in the pancreas, kidney 
or gut (11, 169, 170). Such peripheral deletion in case of CD8+ T cells (cross-tolerance) 
involves CD95-signaling (171) but is mainly mediated by Bim-dependent, Bcl-2 inhibitable 
apoptosis (172).  
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What determines tolerance vs. immunity and what form of tolerance is used is under intense 
investigation. It has been suggested that the strength of TCR signaling determines that anergy 
vs. deletion of CD8 T cells occur. Typically weak, but persistent TCR stimulation causes 
deletion (170, 173). The importance of chronic persistence of antigens has been demonstrated 
by showing that tolerized T cells could survive in vivo once they were removed from the 
antigen bearing host (174). Other survival factors, cytokines such as IL-7, IL-2 were proposed 
to be important for CD8 T cell survival resulting efficient effector and memory responses 
(175-177). The activation status of the antigen presenting cells is generally thought to 
represent a major component in self/non-self discrimination. There are numerous reports 
where the same antigen induced different responses dependent on the presence of adjuvant or 
TLR ligands (100, 107, 178). Accordingly, under steady state conditions continuous 
presentation by immature /resting DC induced peripheral tolerance (13, 173). 
In addition to DC, liver sinusoidal endothelial cells also can induce efficient CD8 T cell 
tolerance (70). Recently an additional mechanism was reported, which depended on Aire-gene 
expressing LN-resident stomal cells that expressed self-antigens themselves and induced CD8+ 
T tolerance (179). 
 
 
4.5.1 Tolerance towards soluble antigens 
 
Cross-tolerance may be required also against certain non-self proteins, such as innocuous self-
serum or food proteins or orally administered antigen. Systemic injection of soluble antigen 
devoid of inflammatory stimuli has been widely used to study such T cell tolerance. Most 
studies have focused on the effect of systemically injected peptides rather than full-length 
protein antigens on T cell tolerance. Such peptides resulted in thymic and peripheral T cell-
apoptosis (180). Further characterization of this phenomenon demonstrated that repeated 
injection of high dose peptide induced anergy whereas repeated injection of low doses resulted 
in clonal deletion. Single injection of low dose peptide antigen could induce only incomplete 
deletion of CD8 T cells (170, 174). Systemic injection of full-length protein antigen have been 
demonstrated to result in mmunological unresponsiveness (178, 181). Cross-tolerance against 
blood-borne soluble antigen is thought to be induced in the spleen, because cross-presentation 
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of such antigen is particularly efficient in this organ (75), but not in LNs (182). Formal proof 
of tolerance against soluble antigen has been provided for the liver (69).  
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5. Aim of this study 
 
Part 1  
Investigating the role of C-type lectins in antigen uptake 
 
Several receptors mediating antigen uptake in DC have been identified, such as the Fc-
receptors, DC-SIGN and DEC-205. A role of the MR in antigen uptake and presentation by 
DC has been proposed based on the finding that mannosylated proteins are presented more 
efficiently than non- mannosylated ones (123). It is unclear; however, whether this uptake was 
due to the MR, as DCs express other receptors, such as DC-SIGN, with affinity for 
mannosylated proteins. The first aim of this study was to overcome these limitations with the 
use of MR-/- mice, in order to elucidate the role of the MR in the uptake and presentation of 
soluble vs. cell-associated ovalbumin (OVA) in vivo.  
 
 
Part 2 
Handling of soluble filtrated molecules by kidney dendritic cells 
 
An unresolved question in the field of antigen presentation is how tissue-derived innocuous 
self-antigens are transported to draining LNs for DC-mediated induction of T cell tolerance. 
Preliminary work in the lab of Prof. Kurts has shown that the kidney enriches innocuous 
circulating protein antigens below albumin molecular size (68 kDa). Such molecules can pass 
the glomerular filter and reach the tubular lumen. To prevent their loss with the urine, they are 
reabsorbed by tubular epithelial cells and released in degraded form into peritubular 
capillaries. Recently, it was shown that filterable dextran molecules are not only taken up by 
tubular epithelial cells, but also by kidney DCs (23). However how the kidney and its dendritic 
cells handle these filtrating soluble molecules immunologically, whether filtrated low 
molecular weight antigens reach the draining LN and what consequences they have for T cell 
activation are unknown. These questions were addressed in this study. 
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6. Materials and Methods 
 
6.1 Materials 
 
6.1.1 Technical equipment 
 
AutoMACS   Miltenyi, Bergisch Gladbach 
Cell culture dishes  25cm2, 80cm2, (Nunc, Wiesbaden) 
Centrifuge tubes  15ml, 50ml (Greiner Labortechnik, Frickenhauser) 
Cover slip (18 x 18 mm) Menzel Gläser, Braunschweig 
Dako Pen   Dako Cytomation GmbH, Hamburg 
Flow cytometer  FACS-Canto und LSR II (BD, Heidelberg) 
Injection needle  25G, 27G (BD, Heidelberg) 
MACS -separator  Miltenyi, Bergisch Gladbach 
MACS - Column  MS+ und VS+ (Miltenyi, Bergisch Gladbach) 
Metal zip   University of Bonn 
Multipipette   Dunn Labortechnik 
Microwave   Bosch, Stuttgart  
Microscope   IX71 (Olympus, Hamburg)   
Neubauer chamber  Brand, Wertheim 
Parafilm   American National Can TM, Greenwich 
Pasteur pipettes   150mm, 230mm (Roth, Karslruhe)  
PD-10 column  Amersham, Uppsala 
Petri-dish   10 cm Ø (Nunc, Wiesbaden) 
Pipettes Gilson, Heidelberg 
Pipette-boy       Hirschmann Labortechnik, Eberstadt 
Reaction tubes  0.5-2mL (Eppendorf, Hamburg) 
Scalpel    Aesculap, Tuttlingen 
Slide    ‘Super Frost Plus’ (Menzel-Gläser, Germany) 
Suture material-absorbable Maxon HR13 (1m, USP 5/10) (Aesculap, Tuttlingen) 
Sterile filter 0.2µm (Nunc, Wiesbaden) 
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UV-irradiation CL-1000 UV Cross-linker (Upland, USA) 
Zip, Nylon-   70μm und 100μm (BD, Heidelberg)   
 
 
6.1.2 Chemicals and reagents 
 
Acetic acid (C2H4O2, MW=60,05)    Roth, Karlsruhe 
Agarose       Invitrogen, Karlsruhe 
Albumin, Bovine serum- (BSA)     Gerbu, Gaiberg 
Alexa647 labeling kit      Molecular probes, Netherlands 
Ammoniumchlorid (NH4Cl, MW = 53,49)   Merck, Darmstadt 
Brefeldin A (C16H24O4, MW = 280,4)   Sigma, Taufkirchen 
Bromphenolblue (C19H10Br4O5S, MW = 670,0)  Sigma, Taufkirchen 
Collagenase A      Roche, Mannheim 
CFA (Complete Freund`s Adjuvant)    Sigma, Taufkirchen 
CFSE  Molecular Probes, Netherlands 
Dimethylsulfoxid (DMSO) ((CH3)2OS, MW = 78,13)  Merck, Darmstadt 
Dinatriumhydrogenphosphat (Na2HPO4, MW = 142,0)  Merck, Darmstadt 
DNAse I       Roche, Mannheim 
DQ-OVA       Molecular probes, Netherlands 
Ethanol, absolute (C2H5OH, MW = 46,07)   Merck, Darmstadt 
Ethidiumbromid (C21H20N3Br, MW = 394,3)   Sigma, Deisenhofen 
Ethylendiamintetraacetate (EDTA)  
(C10H14N2O8Na2 • 2H2O, MW = 372,2)    Gerbu, Gaiberg 
Foetal calf serum (FCS)      PAA, Cölbe 
Foetal calf serum (low LPS, low IgG) (FCS-LPS)  PAA, Cölbe 
L-Glutamine (200mM) (C5H10N2O3, MW = 146,1)  Invitrogen, Karlsruhe 
HCl, MW = 36,46)      Sigma, Taufkirchen 
Heparin       Amersham Pharmacia, Freiburg 
HEPES 1 M (C8H18N2O4S, MW = 238,3)   Invitrogen, Karlsruhe 
Hoechst 33342      Molecular probes, Netherlands 
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Isopropanol ((CH3)2CHOH, MW = 60,1)    Merck, Damrstadt 
Ketamin       Pharmacia GmbH, Karlsruhe 
Lymphoprep         PAA, Cölbe 
2-Mercaptoethanol (HS (CH2)2OH, MW = 78,13)  Sigma, Taufkirchen 
Natriumazid (NaN3, MW = 65,01)    Sigma, Taufkirchen 
Natriumbicarbonat (NaHCO3, MW = 84,01)   Sigma, Taufkirchen 
Natriumchlorid (NaCl, MW = 58,44)   Merck, Darmstadt 
Natriumchlorid (NaCl) 0.9%      B.Braun, Melsungen 
Natriumdihydrogenphosphat (NaH2PO4, MW = 120,0)  Merck, Darmstadt 
Natriumhydrogenphosphat (Na2HPO4, MW = 142)  Sigma, Taufkirchen 
Natriumhydroxid (NaOH, MW = 40,0)   Merck, Darmstadt 
Ovalbumin, Grad V       Sigma, Taufkirchen 
Paraformaldehyde (PFA) (H (-OCH2)n-OH)   Serva, Heidelberg 
PBS         Biochrom, Berlin 
Percoll        Amersham Pharmacia, Freiburg 
Propidium iodide      Molecular probes, Netherlands 
Protein assay kit      Pierce, Bonn  
Rompun       aniMedica GmbH, 
Senden-Boesensell 
RPMI        Invitrogen, Karlsruhe 
Saponin       Sigma, Taufkirchen 
SIINFEKL       Abcam, Berlin 
Triton X-100       Sigma, Taufkirchen 
Trypanblue, 0,4% (C34H24N6O14S4Na4, MW = 960,8)  Biochrom, Berlin 
Trypsin/EDTA      Invitrogen, Karlsruhe 
7AAD (7-Aminoactinomycin D)    Sigma, Taufkirchen 
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6.1.3 Buffers and media 
 
PBS 
PBS: NaH2PO4 20 mM, NaCl 50mM, Ph adjusted to 7.4. It was autoclaved and stored at 4 °C. 
 
PBS containing 0.1 % bovine serum albumin (BSA)  
It was prepared by dissolving 0.1 g BSA (> 98 % purity, Serva, Heidelberg) in 100 ml PBS.  
The solution was sterilized by filtration through a 0.45µm sterile syringe filter. 
 
FACS buffer  
It consisted of PBS containing 0.1 % BSA and 0.01 % NaN3. Solution was stored at 4°C. 
 
MACS buffer 
It consisted of PBS containing 0.1 % BSA, 2mM EDTA. Solution was stored at 4°C. 
 
Red blood cell removal buffer (RCRB)  
It was prepared by dissolving 15.58 g NH4Cl (0.146 M), 0.074 g ethylenediamine-tetra-acetic 
acid (EDTA)-disodium salt, 2.0 g NaHCO3 in 2 litres of Milli Q water.  Final pH = 7.3. 
RCRB was usually pre-warmed to 37°C before use. 
 
4 % acetic acid solution  
It was prepared by mixing 40 ml glacial acetic acid with 960 ml double distilled water. This 
solution was not sterilized. 
 
Carb/bicarb buffer (0.5 M)  
It was prepared by adding 4.4 ml of Na2CO3 solution (5.3 g in 100 ml pure water) to 100 ml 
NaHCO3 solution (4.2 g in 100 ml pure water). PH adjusted to 9.0. 
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20 % Triton X-100  
Solution was prepared by mixing 20 ml Triton X-100 with 80 ml Milli Q water. This solution 
was not sterilised. 
 
EDTA 0.5M 
186.1g Ethylendiamintetraacetat (EDTA) (C10H14N2O8Na2 • 2H2O, MW = 372,2) was solved 
in 800 ml Milli Q water. Ph was adjusted to 8.0 with NaOH than filled up with Milli Q water 
till 1000 ml. Solution was autoclaved and stored at room temperature. 
 
20 % PFA 
40 g of PFA was solved in 200 ml PBS and incubated at 60°C in the water-bath till PFA was 
completely solved. PH was set to 7.4. Aliquots were stored at –20°C, and they were further 
diluted with PBS before use. 
 
Collagenase A stock 
It was solved in PBS at a concentration of 100mg/ml. Aliquots were stored at –20°C. 
 
DNAse I stock: 
It was solved in PBS at a concentration of 10mg/ml. Aliquots were stored at –20°C. 
 
CFSE stock: 
5,6-Carboxy-Succinimidyl-Fluoresceine-Ester (CFSE) was kept as a stock solution (5mM in 
DMSO) and stored at –20°C. 
 
Cell culture media 
RPMI 1640 with HEPES, 10% FCS, 2mM Glutamine, 100 IU/ml Penicillin, 100µg/ml 
Streptomycin, 50µM 2-Mercaptoethanol was prepared. It was stored at 4°C. 
 
0.005 M 2-Mercaptoethanol in PBS 
178µl of 14.3 M 2-Mercaptoethanol was added to 500ml PBS. Solution was kept sterile and 
stored at 4°C. It was further diluted 1:100 in media. 
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6.1.4 Antibodies 
 
Antigen Isotype Clone Notes Source 
CD4 IgG2b κ, Rat GK1.5  BD 
CD8α IgG2a κ, Rat 53-6.7 = Ly-2 BD 
CD11b IgG2b κ, Rat M1/70 = Integrin αM, Mac-1 chain BD 
CD11c IgG1, hamster HL3 = Integrin αX chain BD 
CD16/32 IgG2b κ, Rat 2.4G2 = Anti-FCγR III + II / unconjugated hybridome 
CD25 IgG2b κ, Rat 3C7 = IL-2-Rezeptor-alpha chain BD 
CD40 IgG2a κ, Rat 3/23  BD 
CD44 IgG2b κ, Rat IM7 = Pgp-1, Ly-24 BD 
CD49d IgM κ, Rat   BD 
CD62L IgG2a κ, Rat MEL-14 = L-selectin, LECAM-1, Ly-22 BD 
CD69 IgG1, 
Hamster 
H1.2F3  BD 
CD80 IgG2, 
Hamster 
16-10A1 = B7.1 BD 
CD86 IgG2a κ, Rat GL1 = B7.2 BD 
F4/80 IgG2b, Rat F4/80  BD 
MHC II IgG2a κ, Rat 2G9 I-Ad / I-Ed / bind also H-2b BD 
MHC II IgG2a κ, 
Mouse 
KH74 I-Ab / bind also I-Af, r, s, + v BD 
Vα2 TCR IgG2a λ, Rat B20.1  BD 
Vβ5 TCR IgG1 κ, 
Mouse 
MR9-4  BD 
CD206 IgG2a, rat MR5D3 Mannose receptor Serotec 
  SF1 Bm1 screening hybridome 
BODYPY IgG, rabbit  Anti-BODYPY-FL – DQ quenching  Mol. 
Probes 
 
 36
The used antibodies were either biotinilated or conjugated with different fluorochrome (FITC, 
PE, PerCP-Cy5.5, Pe-Cy7 or APC)  
 
Streptavidin conjugated secondary antibodies: 
FITC     BD (Heidelberg); 
PE    BD (Heidelberg)  
APC     BD (Heidelberg)  
PerCPCy5.5      BD (Heidelberg) 
Pe-Cy7   BD (Heidelberg) 
Anti-rabbit-Alexa647  Molecular Probes (Netherlands) 
 
- 7-Aminoactinomycin D (7-AAD) (C62H87N13O16, MW = 1270,45) (Sigma, 
Taufkirchen) 
- PI – propidium iodide (Molecular probe, Netherlands) 
- Hoechst 33342 (Sigma, Taufkirchen) 
- Annexin V – bio BD (BD, Heidelberg) 
 
Magnetic beads: 
- α-Murine CD8-, CD11c- MicroBeads (Miltenyi, Bergisch Gladbach) 
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6.2 Mouse lines 
 
1. Bm1: C57BL/6 mice bearing the mutant Kb molecule was provided by Dr. W.R. 
Heath, Melbourne, Australia. 
2. C57BL/6:  MHC Haplotype H-2Kb were bred at local animal facility (HET, University 
of Bonn) 
3. OT-I mice: Vα2Vβ5 TCR recognises SIINFEKL in the context of H-2Kb. Dr. W.R. 
Heath, Melbourne, Australia, provided OT-I mice, on Rag-1-/- background. 
4. RAG2-/-: Dr. Frank Tache provided these mice, on a C57BL/6 background. (Aachen) 
5. MR-/-: MR-/- mice on a C57BL/6 background were generated and provided by Dr. 
Michel C. Nussenzweig  
6. CCR7-/-: mice on a C57BL/6 background were generated and provided by Prof. Dr. 
Martin Lipp. 
 
For all experiments, mice between 8 and 16 weeks of age bred under SPF conditions were 
used in accordance with local animal experimentation guidelines.  
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6.3 Methods 
 
 
Injection of soluble tracers 
 
Tracers were diluted in PBS and injected intravenously in total volume 400µl. Animals were 
scarified after different time points. 
 
 
Flow Cytometry 
 
In general, approximately 106 cells were washed with 2 ml FACS buffer, centrifuged and the 
supernatant discarded.  20 µl of FACS buffer containing the appropriate primary monoclonal 
antibodies were then added to the cells and the cells were incubated for 30 minutes on ice.  
The cells were then washed in 2 ml of FACS buffer and where necessary, 20 µl of the 
secondary antibody was added and the cells were incubated for a further 30 minutes on ice.  
After an additional washing step, the cells were resuspended in 500µl FACS buffer and stored 
on ice. 
Dead cells were excluded with either PI (0.5 µg/ml), 7AAD (0.5µg/ml) or by using Hoechst-
33342 dye. Flow cytometry was performed on an LSR II (BD) or on FACS-CANTO (BD). 
Doublets were excluded using FCS-w/SSC-a gate. Data were analyzed using Flow-Jo software 
(Tristar, Ashland, OR), including calculation of division indices, which indicate the average 
number of cell divisions.  
 
 
Removal of red cells 
 
Single cell suspensions were depleted of red blood cells by centrifuging and resuspending in 
5-10 ml RCRB for 1 minute. Cells were then centrifuged and resuspended in the appropriate 
medium. 
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Live cell counts 
 
50 µl was taken from a single cell suspension of known volume and was mixed, by pipetting, 
with 50 µl of Trypan Blue Solution. 50 µl of the resulting suspension was then mixed, by 
pipetting, with 50 µl of a 4 % acetic acid solution to kill red blood cells. Live cells (Trypan 
Blue excluding cells) were then counted under a light microscope using a Neubauer chamber. 
 
 
Centrifugation  
 
Lymph node, bone marrow, spleen or kidney cell suspensions were centrifuged in 14 ml or 50 
ml tubes for 5 minutes at 450 g at 4°C. 5 ml polystyrene tubes (flow cytometry) were 
centrifuged for 5 minutes at 200 g at 4°C. 96-well plates were centrifuged for 3 minutes at 200 
g at 4°C. 
 
 
Intracellular cytokine staining 
 
Single cell suspension was prepared and cells were restimulated for 5 hrs in the presence of 
GolgiPlug (BD Bioscience Heidelberg Germany). Cells were fixed for 15 min at 4°C with 2 % 
Paraformaldehyde in PBS. Than washed and incubated for 20 min in PBS 0.1% BSA, 0.5 % 
saponin, which was followed by additional 30 min of incubation with the fluorochrome-
conjugated antibody in PBS 0.1 % BSA, 0.5 % saponin and unconjugated rat IgG. 
 
 
Annexin V staining 
 
Cells were washed with PBS and 106 cells were resuspended in 100µl 1x binding buffer (BD, 
Heidelberg) and added 5 µl Annexin V-bio/sample (BD, Heidelberg). Cells were incubated at 
room temperature for 15 minutes followed by washing with binding buffer. They were further 
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incubated with SA-Fitc (BD, Heidelberg) together with 7AAD for 15 more minutes. After 
washing with binding buffer, samples were analysed immediately by flow cytometry. 
 
 
Histology 
 
Cyrosections from kidney were air dried and fixed with 4 % PFA, followed by blocking with 
PBS containing 3 % BSA for 2 hrs. Samples were stained with anti-BODYPY antibody 1: 300 
in PBS 3% BSA for overnight at 4 °C, than were washed 3 times with PBS. As secondary 
antibody anti-rabbit Alexa-647 was used for 30 minutes at room temperature. After several 
washing step for nuclear staining Hoechst-33526 dye was used. 
 
 
FITC conjugation 
 
The 100mg/ml OVA concentration was used to label with FITC. 25 µl of carb/bicarb buffer, 
pH 9.2 was then added for every 0.5 ml of protein solution. Fluorescein-5-isothiocyanate 
(FITC) (Sigma. Taufkirchen) was weighed, dissolved in DMSO to give 1.5 mg/ml and 
immediately added to the antibody. The tube was covered in foil and gently rotated at room 
temperature for 30-40 minutes. A Sephadex G-25 column (Pharmacia Biotech, Uppsala, 
Sweden) was then washed with several ml of PBS and loaded with the FITC-conjugated OVA. 
The column was eluted with 2.5 ml PBS and the first band containing the FITC-conjugated 
OVA was collected.  
 
 
Preparation of fluorescent soluble and cell-associated OVA 
 
Soluble OVA was conjugated to a fluorochrome using an Alexa647 labelling kit (Invitrogen, 
Karlsruhe, Germany). Labeling procedure was carried out according to the manufacturer’s 
guidelines. The labeling procedure involved gel-filtration as a final step for removal of low 
molecular weight molecules such as unbound fluorochrome. For cell-associated OVA, 
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splenocytes from Bm1 mice (2.108 cells/ml) were incubated with 10 mg/ml OVA-FITC for 10 
min at 37°C, UV-irradiated with 15 mJ for 5 min and washed extensively.  
 
 
Cross-presentation assay in vivo 
 
OT-I cells were isolated from OT-I Rag-/- mice as described before (25). OT-I mice producing 
OVA-specific CD8 + T cells were crossed to a RAG-l-/- background to prevent endogenous 
rearrangement of TCR and to avoid generation of CD4+ T cells and B cells. Spleen and lymph 
nodes were collected and single cell suspension was prepared. To remove erythrocytes 
erythrolysis buffer (146mM NH4Cl, 10mM NaHCO3, 2mM EDTA) was used. Cells were 
labeled with 5- (and -6) carboxyfluorescein diacetate, succinimidyl (CFSE, Invitrogen, 
Karlsruhe, Germany) described before (183). Briefly 10-20 x 106 cells/ml were resuspend in 
PBS (Phosphate buffered saline) containing 0.1 % BSA (Bovine serum albumin type H1 
GERBU, Germany), 5µM CFSE and stained at 37 °C for 10 minutes. Cells were washed with 
PBS; debris and aggregates were removed by filtering the cell suspension through a 70 µm 
mesh. Before adoptive transfer OT-I cell preparations were analyzed by flow cytometry. 
Suspension usually contained 70-85 % OT-I transgenic CD8 + T cells. 2x106 OT I cells were 
injected intravenously into recipient mice.  
For priming mice with soluble protein, OVA (grade V) was dissolved in PBS, to avoid peptide 
contamination gel filtration was performed using Sephadex G-25 (PD10 column, Amersham) 
according to manufacturer’s protocol. Protein concentration was determined using BCA 
protein assay (Pierce, Bonn, Germany). 10µg/mouse g of soluble OVA was injected in 400µl 
PBS intravenously. An emulsion of 200µg OVA and 100µl CFA (Sigma Aldrich) was injected 
s.c into the flank of the mice. 
 
 
Cross-presentation assay in vitro 
 
20 minutes after injection of 1.5mg OVA, DCs were isolated from spleen and kidney. OT-I 
cells were isolated from OT-I rag-/- mice and further purified by a microbead- based CD8 T 
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cell isolation kit (Miltenyi). Purity was typically higher than 96 % of viable cells; 
contaminating CD11c+ cells were typically rarer than 0.2 %, NK1.1+ cells rarer than 0.03 %, 
and CD4+ cells were below 1 %. 5 x 104 DC were co-cultured with 2 x 105 CFSE labelled T 
cells and proliferation was assayed 48-72 hrs later by flow cytometry. 
 
 
Isolation of DC from experimental animals 
 
Cells were isolated from spleen and lymph nodes with digestion with Collagenase A (Roche 
Diagnostic, Mannheim Germany) and DNAse-I (Sigma Aldrich, Steinheim, Germany). For the 
preparations from the bone marrow, cells were collected after flushing through the femurs and 
tibias with PBS. Kidney was digested for 1 hrs at 37 °C using Collagenase A and DNAse-I 
and single cells suspension was let in MACS buffer at 4°C for 10 minutes to settle down 
tubular compartments, the upper 3/5 part of this cell suspension was further used either for 
staining or for CD11c MACS separation. CD11c+ cells were in some cases enriched by 
magnetic separation using LS25 or MS25 columns (Miltenyi). Purity was typically higher than 
85 %. 
 
 
In vivo cytotoxicity assay 
 
In vivo cytotoxicity assays were performed as described (184). In brief, spleen cells were 
either pulsed with SIINFEKL (1 µg/mL, 45 min at 37°C) and labeled with a high 
concentration of CFSE (1 µM, 15 min at 37°C; CFSE high cells) or were mock treated and 
labeled with a low concentration of CFSE (0.1 µM; CFSE low cells). Cells were washed twice 
with PBS and equal numbers of cells from each population were injected i.v. (1x107 target 
cells). Animals were killed 4 h later and the presence of target cells in spleen and lymph nodes 
was analyzed by flow cytometry. To calculate specific lyses the following formula was used:  
% specific cytotoxicity = 100 – (100 x (CFSEhigh / CFSElow) primed / (CFSEhigh / CFSElow) control). 
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Nephrectomy 
 
Mice were anaesthetised (Ketamin (Pharmacia GmbH, Karlsruhe, Germany) 0.1 mg/g 
bodyweight and Rompun (aniMedica GmbH, Senden-Boesensell, Germany) 2 % 0.01 mg/g 
bodyweight). Nephrectomy was carried out as described before (25). Briefly, the abdominal 
cavity is entered from the basolateral side; the kidney is freed from surrounding tissue and is 
pulled out of the incision gently. The adrenal gland, which attached loosely to the anterior pole 
of the kidney is gently freed and returned to the abdominal cavity. The renal blood vessels and 
the urether are cauterized and the kidney is removed. 
 
 
Transfer experiment 
 
C57Bl/6 mice were injected with 2 million CFSE labeled OT I cells. Next day they were 
primed with OVA (10µg/g) i.v. or with OVA-CFA s.c.. On day 2 total renal LN cells were 
pooled from 6-8 animals, and together with the cLN cells from OVA-CFA primed animal 
aliquot was taken for analysis of TCR and CD8 expression. Than cells were transferred into 
Rag-/- recipients and 12 days later LN and spleen was collected from the Rag-/- mice and 
analyzed for TCR and CD8 expression.  
 
 
Statistical analysis 
 
Results are expressed as mean ± standard deviation (SD). Comparisons were drawn using a 
two-tailed Student's t-test (Prism 4, Graphpad Software Inc., San Diego CA USA). 
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7. Results 
 
 
7.1 Part 1: The mannose receptor mediates uptake of soluble, but not of cell-
associated antigen for cross-presentation 
 
7.1.1 Dendritic cells in the secondary lymphoid organs express MR in vivo 
 
The role of the MR in antigen uptake and presentation by DCs was proposed based on studies 
in human dendritic cells in vitro (95, 121). Recently it has been also conformed in the lab of 
Prof. Kurts in murine bone marrow derived DCs (182). To elucidate the role of MR in antigen 
presentation in vivo, first the expression of MR was determined in secondary lymphatics by 
flow cytometry. Using conventional surface staining, only weak MR expression was detected 
on DCs isolated from spleen, BM or cLN. However, intracellular staining revealed the 
presence of the MR in all organs tested (Fig. 6). 
 
 
Figure 6. MR expression in different 
secondary lymphoid organ 
DC from spleen, BM, cLN were isolated from 
C57Bl/6 and MR deficient mice and 
subsequently stained for CD11c and MR. For 
MR cells were stained intracellularly. Shown 
are the viable CD11c+ cells present in the 
different organs. 
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7.1.2 Uptake of soluble antigen by DC in vivo is mediated predominantly via 
the MR  
 
To clarify the in vivo handling of soluble molecules in DC possibly mediated by MR, 
ovalbumin (OVA) as a model antigen was used.  
After injection of fluorochrome-labeled soluble OVA into C57Bl/6 mice, DCs were isolated 
from the spleen. The uptake of soluble OVA by these cells showed close correlation with the 
expression of the MR (Fig. 7). A small proportion of captured OVA however was not in MR+ 
DCs indicating that this molecule was taken up by DCs via an MR-independent mechanism.  
 
 
Figure 7. Uptake of soluble OVA in vivo is mediated predominantly via the MR 
C57Bl/6 mice were i.v. injected with aOVA (5µg/ body weight). After 45 minutes, spleen was digested 
with Collagenase and DNAse-I containing medium. The resulted single cell suspension from the spleen 
was stained for surface expression of CD11c and for intracellular expression of the MR. 
 
 
Consistent with above finding, systemic injection of Alexa-647 labeled OVA (aOVA) into 
MR-/- mice showed significant but incomplete reduction of uptake in DCs isolated from 
spleen, cLN and bone marrow (Fig. 8 A, B). The decline was most evident in the spleen and in 
the bone marrow. In the cLN, only moderate endocytosis of aOVA could be observed, which 
was further reduced in MR-/- mice, albeit not significantly (Fig 8 A, B).  
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Figure 8. Uptake of soluble OVA in vivo is mediated predominantly via the MR 
A Wildtype and MR deficient mice were i.v. injected with aOVA (5µg/body weight). After 45 
min, DC were isolated from the spleen, BM, and cLN and analyzed by flow cytometry. 
Numbers give the proportions of aOVA+ cells ± SD within the viable CD11c+ cells. (n=3 or 4 
mice) 
B MFI ± SD of the viable CD11c+ cells from B. 
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To rule out that the above reduction of OVA uptake was due to changes of DC subpopulations 
present in MR-/- mice, the percentage of CD8α+ lymphoid and CD11b+ myeloid DC were 
determined in the different organs. Both DC subtypes in MR deficient mice compared to 
wildtype were unaltered. The percentages ± SD is summarized in table 1. 
 
 CD8α+ CD11b+
BM wildtype / MR-/- 6.25 ± 1.2 / 6.5 ± 0.9 32.6 ± 0.2 / 29.25 ± 3.6 
Spleen wildtype / MR-/- 26.55 ± 0.4 / 25.5 ± 1.9 42.8 ± 0.8 / 43.9 ± 1.1 
cLN wildtype / MR-/- 19.45 ± 0.2 / 19.2 ± 1.4 35.1 ± 2.9 / 31.65 ± 0.5 
 
Table 1. Percentage of CD8α+, CD11b+ DCs in wildtype and MR-/- mice 
DCs were isolated from wildtype and MR-/- animals from spleen, cLN, and bone marrow and stained 
for CD11c, CD11b and CD8. Percentages are given ± SD (n=3 animals/group)  
 
 
These findings demonstrated that the MR was involved also in the in vivo uptake of soluble 
OVA, but it was not essential, as opposed to its role in vitro (182). Indeed, some DC had taken 
up OVA but did not express MR. The mechanisms that partially compensated for the absence 
of MR in vivo remain to be identified  
 
 
7.1.3 MR is dispensable for in vivo uptake of cell-associated antigen 
 
In order to compare the fate of soluble and cell-associated antigens in vivo intravenously 
injected bm1 splenocytes were used to carry the antigen to DCs located in the different organs. 
For the uptake experiments bm1 splenocytes were loaded with FITC-labeled OVA. In order to 
demonstrate efficient antigen delivery into these cells, loading with FITC-labeled OVA was 
performed at 4 °C and at 37°C, since intracellular uptake is energy dependent as opposed to 
extracellular coating. Indeed, uptake at 37°C was significantly higher than at 4°C, suggesting 
that some of the antigen was actively endocytosed by these splenocytes (Fig 9). After OVA-
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coating apoptosis was induced by UV irradiation followed by immediate injection of these 
cells into recipient mice (about 30 % of the cells were Annexin-V+ and PI-, apoptotic). 
 
 
Figure 9. Bm1 splenocytes were loaded with Fitc-OVA  
Bm1 splenocytes were incubated with Fitc-OVA for 10 min at 37°C and 4°C and than analyzed for  
uptake of fluorescent soluble antigen by flow cytometry. 
 
 
UV-irradiated bm1 splenocytes loaded with FITC-OVA were injected i.v. into MR deficient 
and wildtype mice. DCs from the spleen and from the bone marrow of C57Bl/6 mice showed 
significant, and the cLN only marginal uptake of cell-associated antigen, consistent with 
reports by others (Fig. 10 A, B) (40, 55). However in MR deficient mice, uptake was 
unaltered, implying that cell-associated antigen had been internalized by mechanisms other 
than MR-mediated endocytosis. 
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 Figure 10. MR is dispensable 
for in vivo uptake of cell-
associated antigen 
A Fitc-OVA loaded Bm1 
cells (20 x 106) were UV 
irradiated and injected into 
wildtype and MR deficient 
mice. 1hr later, DCs were 
isolated from spleen, BM and 
cLN, and the proportion of 
aOVA+ cells in the viable 
CD11c+ cells was determined. 
(n=3 or 4 mice) 
B MFI ± SD of the cells 
from A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.1.4 The MR contributes to in vivo activation of CD8+ T cell by cross-
presentation of soluble but not of cell-associated antigen 
 
To assess the in vivo role of the MR for CD8 T cell activation by cross-presentation, CFSE-
labeled OT-I transgenic T cells were injected into wildtype and MR-deficient mice. Two days 
after priming with soluble OVA, the proliferation of OT I cells in spleen, bone marrow, and 
cLN were analyzed. In MR-/- mice, proliferation of these T cells was significantly diminished, 
suggesting MR mediated endocytosis in DCs shuttle antigens for the cross-presentation 
pathway also in vivo (Fig. 11 A, B).  
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In order to demonstrate the cross-presentation of cell-associated OVA, antigen loaded and UV 
irradiated bm1 splenocytes were used. Bm1 mice bear a mutant H2-Kb protein that cannot 
present OVA to OT-I cells allowing the exclusion of direct presentation by antigen carrying 
cells, thus only the recipient DCs after capturing and processing the antigen containing 
splenocytes were able to induce CD8 T response, as reported by others before (36). 
Proliferation of OT I cells in the spleen and in the bone marrow was not reduced in MR-/- 
mice in agreement with the equal uptake capacity of this antigen type in both mice (Fig. 10 A, 
B and Fig. 12 A, B). Furthermore, in the cLN no proliferation of OT I cells was observed in 
consistent with the marginal antigen uptake occurring in this location in vivo (Fig. 10 and 12 
A, B). Thus, mechanisms other than MR-mediated antigen uptake were responsible for CD8 T 
cell activation by cross-presentation of cell-associated antigen. 
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Figure 11. MR contribute to the in vivo activation of CD8+ T cell by cross-presentation of soluble 
OVA 
A CFSE-labeled OT I cells (2 x 106) were injected into wildtype and MR deficient mice. After 18 
hrs, 5µg OVA /body weight was injected i.v. After an additional 40 hrs, the proliferation of 
OT-I cells was analyzed in the spleen, BM, and the cLN. Shown are the living CFSE+CD8+ 
cells present in the different organs. 
B Division indexes of proliferating cells from experiment A. 
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Figure 12. MR does not contribute to the in vivo activation of CD8+ T cell by cross-presentation 
of cell-associated OVA 
A CFSE-labeled OT I cells (2 x 106) were injected into wildtype and MR deficient mice. After 18 
hrs, 20 x 106 OVA-loaded, UV irradiated splenocytes were injected i.v. After an additional 40 
hrs, the proliferation of OT-I cells was analyzed in the spleen, BM, and the cLN. Shown are the 
living CFSE+CD8+ cells present in the different organs. 
B Division indexes of proliferating cells from experiment A. 
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The next experiment was designed to ensure that the phenotype observed above in CD8+ T cell 
proliferation was due only to the inability of DCs to efficiently capture soluble OVA in the 
absence of MR rather than other factors such as abolishment in recirculation of OT I cells 
activated elsewhere. First CD69 expression on OT-I cells was determined 15 hrs after priming. 
In case of cell-associated antigen no alteration was observed in the upregulation of CD69 on 
the activated T cells (Fig. 13 A). The percentage of CD69+, activated OT I cells was 
significantly reduced in MR deficient mice after priming with soluble OVA, indicating a 
diminished CD8+ T cell activation in situ (Fig. 13 A). 
Moreover, the level of co-stimulatory molecules expressed on DC showed no difference 
between wildtype and MR deficient mice (Fig. 13 B), indicating that variations in 
costimulation could not explain the reduced activation of CD8+ T cells in the presence of 
soluble OVA.  
Taken together, the diminished proliferation of OT I cells was due to the decreased antigen 
uptake capacity of DC via the MR, thereby causing limited activation of antigen specific T 
cells at the priming site. 
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Figure 13. No effect of MR on the expression of CD69 on activated T cell and on expression of 
costimulatory molecule by DC 
A CFSE-labeled OT I cells (2 x 106) were injected into wildtype and MR deficient mice. After 18 
hrs, 20 x 106 OVA-loaded, UV irradiated splenocytes or 5µg OVA / body weight were injected 
i.v. After an additional 15 hrs, the CD69 expression of OT-I cells was analyzed in the spleen. 
Shown are the CFSE+CD8+ cells present in the spleen. 
B DCs were isolated from wildtype and MR deficient mice and surface staining was carried out 
in order to analyze the expression of costimulatory molecules such as CD86, CD80, and CD40. 
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7.1.5 The MR and the cross-presenting APC in the spleen 
 
It has been described that CD8+ DC were responsible for the cross-presentation of both cell-
associated and soluble antigen in the spleen (37, 39). Only CD8+ DCs had been previously 
shown to capture apoptotic, dying cells from the circulation (40, 55). Indeed, MR deficient 
mice did not show alteration in CD8+ DC mediated uptake of cell associated OVA (Fig. 10, 14 
A). In case of soluble antigen however, both lymphoid and myeloid splenic DC were capable 
of endocytose soluble OVA from the blood in consistent with previous findings (39) (Fig. 14 
B). MR deficient mice showed a reduction of aOVA in splenic DC (Fig. 8 A, B), which raised 
the question whether the reduction in the uptake was DC subtype specific. Indeed, expression 
of MR by freshly isolated splenic DC was exclusively restricted to the CD8+ subset. Thereby 
expression of MR allows distinguishing between DCs that are capable of cross-presentation. 
Taken together, the expression of MR, besides CD8α (37) and Dec-205 (185), another 
absolute marker expressed exclusively by the cross-presenting APC in vivo.  
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Figure 14. The MR and the cross-presenting DC in the spleen 
A Wildtype and MR deficient mice were injected i.v with 20 x 106 Fitc-OVA loaded and UV 
irradiated splenocytes. 1 hr later DC from spleen were prepared and analyzed for CD8 
expression. Shown are viable CD11c+ cells. 
B Wildtype mice were injected i.v with 5µg/ body weight aOVA. 45 min. later DC from spleen 
were prepared and analyzed for CD8, and CD11b expression. Shown are viable CD11c+ cells. 
C DC were isolated from wildtype mice and stained for MR and CD8. Shown is the viable 
CD11c+ cells gated on CD8- and CD8+ after doublet exclusion.  
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7.2 Part 2: Lymph node-resident dendritic cells induce T cell cross-tolerance 
against tissue-derived antigen 
 
7.2.1 Kidney dendritic cells preferentially endocytose filtrated antigens 
 
Molecules below albumin molecular size (68 kDa) pass the kidney glomerular filter and are 
reabsorbed by tubular epithelial cells and kidney dendritic cells (kDC) (23, 30, 31). This 
suggested that the concentration of the glomerular filtrate in the tubular system might cause 
enrichment of filtrated proteins in kDC. To test this hypothesis, Alexa647-labeled OVA 
(aOVA) and 500 kDa FITC-labeled dextran were co-injected i.v. into C57Bl/6 mice. The large 
dextran served as marker for non-filterable molecules, which DC can acquire only from the 
blood. In contrast, aOVA should be available also from the tubular ultrafiltrate, because its 
molecular weight of 45 kDa renders it filterable. 20min after injection, DC from the spleen 
and from cutaneous LNs (cLNs) had internalized both aOVA and FITC-dextran (Fig. 15). 
Splenic DC endocytosed both molecules more efficiently, but the ratio between them was 
similar (note the lines in Fig. 15). In contrast to this, kDC efficiently endocytosed aOVA but 
little FITC-dextrane (Fig. 15) indicating superior uptake of filtrated molecules and inferior 
uptake of blood-borne molecules. 
 
Figure 15. Selective uptake of filtrated antigen by kDC 
C57Bl/6 mice were i.v. injected with 8µg/g body weight of Alexa647-labeled OVA (aOVA) and of 500 
kD FITC-dextran. After 20 min, CD11c+ DC from the cutaneous LN (cLN), the kidney and the spleen 
were analyzed for fluorescence uptake. A line was added to the dot-plots to indicate the ratio between 
uptake of small and large molecules. Note that in kidney DC (kDC), this ratio was in favor of small 
molecules. 
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7.2.1.1 Enrichment of filtrated antigen in the kidney is remarkably fast  
 
 
Figure 16. Rapid uptake of filtrated antigen by kDC 
A Mice were i.v. injected with 8µg/g body weight aOVA. After 30 sec or 10 min, fluorescence 
uptake by CD45– intrinsic kidney cells, and CD11c+ kDC was determined. Numbers in the lower 
right dot-plots give proportions of DC containing aOVA ± SD (n=3).  
B Statistical analysis of the MFI of aOVA uptake in Fig. 16 A. Background MFI of cells from 
uninjected animals was subtracted (n=3). 
 
 
The kidney DC acquired i.v. injected aOVA very rapidly. Already 30 sec after injection, about 
12 % of the kDC had accumulated some aOVA (Fig. 16 A). After 10 min, the mean 
fluorescence intensity (MFI) had risen more than 5-fold (Fig. 16 A, B), and antigen was 
detectable within nearly half of the kDC, equivalent to 30–50x103 DC per kidney. Uptake of 
aOVA was even larger in kidney cells deficient for the common leukocyte marker CD45 (Fig. 
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16 B). Histology identified these cells upon their typical morphology as tubular epithelial 
cells, consistent with their established function of reabsorbing filtrated protein (Fig. 17.) (28). 
 
 
Figure 17. Rapid accumulation of filtrated antigen in tubular cells of the kidney 
Mice were i.v. injected with 8µg/g body weigh of DQ-OVA. After 10 min, fluorescence uptake was 
determined by anti-BODIPY + anti-goat Alexa-647 antibody (red), nucleus was stained with Hoechst 
(blue), the high autofluorescence of the kidney shown in green. A shows uninjected, B injected animal.  
 
 
7.2.1.2 DC of the myeloid phenotype endocytose filtrated antigens but do not 
induce T cell activation ex vivo  
 
DC in the kidney that endocytosed filtrated molecules showed the CD11b+ myeloid phenotype 
(Fig. 18 A), whereas CD8α+ lymphoid and Gr-1+ plasmacytoid DC were absent (Fig. 18 A). 
Later is consequent with previous findings that these DC subtypes are completely absent in the 
normal kidney (21). Endocytosis of aOVA by kDC did not result in DC maturation as 
evidenced by lack of CD80 or MHC II upregulation (Fig. 18 B).  
In vitro co-culture of antigen specific T cells (OT-I) with kidney DCs isolated from soluble 
OVA injected animal did not result in efficient T cell activation compared to splenic DC 
isolated from the same injected animal. (Fig. 19) Nevertheless, kDCs coated with SIINFEKL 
were able to induce T cell proliferation similar to splenic DCs, suggesting that the difference 
in the observed phenomenon is not dependent on the level of co-stimulation expressed by 
kDC.  
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Figure 18. Phenotypic analysis of kDCs endocytosed filtrated molecules  
A Expression of CD11b, CD8α and Gr-1 by CD11c+ kDC. Dot-plots show results typical of 3 
individual experiments. 
B Expression of CD80 and MHC II by CD11c+ kDC before (dashed line) and 1 h after aOVA 
injection aOVA (tinted). Isotype controls are shown as bold lines. 
 
 
Figure 19. In vitro ability of kDC to induce CD8 T cell response 
C57Bl/6 mice were injected with 1.5 mg OVA, 20 minutes later dendritic cells from kidney and spleen 
were isolated. 5x104 DCs were co-cultured with 2x105 CFSE labeled OT-I cells. Proliferation was 
measured 72 hrs later by FACS. As a positive control kidney and splenic DC from uninjected animals 
coated with SIINFEKL was used.  
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7.2.2 Rapid cell independent transport of filtrated antigen to rLN DC 
 
 
7.2.2.1 Enrichment of filtrated molecules in rLNs elicited particularly fast 
kinetic and was dependent on filtration process occurring in the kidney 
 
As has been reported before kidney autoantigens are presented to CD8+ T cells in the rLN (11, 
25). To test whether also antigen filtrated in the kidney reached this LN, mice were injected 
i.v. with aOVA and uptake by rLN cells was determined. In order to distinguish aOVA taken 
up from the circulation and aOVA arriving from the kidney, the rLNs were compared to a 
kidney non draining LN, which could acquire antigen only from the circulation such as the 
cLN. Indeed, more cells captured aOVA in rLNs than in cLNs (Fig. 20 A), and higher antigen 
uptake was detected as shown by the comparison of mean fluorescence intensity (MFI) of 
aOVA in CD11c+ cells (Fig. 20 A, B), indicating the presence of excess kidney-derived 
filtrated aOVA in the rLNs. Importantly, the superior aOVA accumulation in the rLNs over 
the cLN was seen already 90 sec after aOVA injection and was further elevated after 5 min 
(Fig. 20 A, B). Additionally, this fast enrichment was dependent on the filtration process 
occurring in the kidney, since left nephrectomy (NX) before aOVA injection abrogated 
accumulation of filtrated antigen in the left rLN, while that in the right rLN remained 
unaffected (Fig. 20 C). At the site of the nephrectomy, rLN showed uptake comparable to that 
in cLN, indicating similar abilities for both LN to acquire antigens from the blood. Thus, 
aOVA accumulation in rLNs depended on its enrichment in the kidney, rather than on 
particularities of these LNs such as microcirculation or special localization close to major 
vessels.  
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Figure 20. Rapid accumulation of filtrated antigen in rLN DC 
A C57Bl/6 mice were injected i.v. with 8µg/g body weight aOVA. After 90 sec or 5 min, cells from 
rLNs and cLNs were stained for CD11c. Dot plots show typical aOVA content and CD11c 
expression in total viable 7AAD– LN cells.  
B Statistical analysis of Fig. 20 A, giving MFI of CD11c+ DC 90 sec and 5 min after aOVA injection 
(n=5 mice). 
C 8µg/g body weight aOVA was i.v. injected one day after surgical removal of the left kidney. 
aOVA content in CD11c+ DC was detected in the left and right rLN and in the cLN (n=6 mice, 
rLNs from two animals were pooled for analysis). 
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7.2.2.1 Filtrated antigen accumulates predominantly in CD11clo and 
moreover reaches some CD8α+ DCs of the renal LN 
 
Most rLN cells that contained filtrated aOVA were CD11c+ CD11b+ conventional myeloid 
DC, while CD11c– CD11b+ macrophages represented a minority (Fig. 20 A, Fig. 21 A). The 
absolute number of aOVA+ DC was about 20-fold lower in one rLN than in one kidney (Fig. 
21 B). Interestingly, in rLNs, aOVA was detected mostly in CD11clo DC (Fig. 20 A, 21 A), 
whereas aOVA+ DC in the kidney were predominantly CD11chi (Fig. 16 A). The rLN differed 
from the kidney also by containing some CD8α+ DC that had captured aOVA (Fig. 21 C). 
 
 
 
 
Figure 21. Phenotype of cells accumulating aOVA in the rLN  
A Proportions of CD11clo, CD11chi DC and of CD11c– CD11b+ cells within the aOVA-containing 
rLN cells from Fig. 20 A. 
B Absolute numbers of CD11c+ aOVA+ DC in one kidney and in the left rLN (n=3 mice) 
C Viable CD11c+ DCs in rLNs were analyzed for CD8α expression and aOVA uptake. Doublet 
events were excluded by FSC-w gate. The number gives mean ± SD of CD11c+ positive for both 
parameters (n=3). Without doublet exclusion, this value was 2,8 ± 0.5 %.  
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7.2.2.2 Antigen uptake in rLNs depends on the MR, but not on CCR7 
 
These phenotypic differences between aOVA+DC in the kidney and renal LN and the rapid 
kinetics of aOVA accumulation suggested cell-independent antigen transport into rLNs. To 
test this hypothesis, recent discovery was used that endocytosis of soluble OVA by DC was 
facilitated by the mannose receptor (MR) (Fig. 8 A, B). As expected, this receptor was used by 
rLN DC for uptake of filtrated aOVA, as evidenced by lack of this uptake in MR–/–mice 5 min 
after injection. (Fig. 22 A). In contrast, kDC had internalized somewhat less aOVA at this time 
(Fig. 22 A), and this occurred in a MR-independent fashion in consistent with that MR 
expression was not detectable by kDCs (Fig. 22 B) The absence of DC containing high 
amounts of MR-endocytosed aOVA from the kidney argued against this organ as origin of 
such DC in rLNs. Suggesting LN-resident DCs have taken up and accumulated filtrated 
antigens arriving from the kidney presumably via the lymphatics in a cell independent manner.  
 To confirm this interpretation, uptake of OVA was investigated in CCR7–/– mice, in which 
DC migration from non-lymphoid organs to their draining LN is incapacitated (156). Despite 
this defect, rLN DC of CCR7–/– mice showed unimpaired accumulation of DQ-OVA (Fig. 22 
C), an alternative tracer for filtrated antigen. However the percentage of CD11c+ cells was 
lower in rLN derived from CCR7-/- animal; possibly due to impaired migration of kDC; the 
DCs present in rLN showed no significant difference in the amount of captured DQ-OVA 
(Fig. 22 B). These findings verify that rapid antigen transport must have occurred cell-
independently. 
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Figure 22. Antigen uptake in rLNs depends on the MR, but not on CCR7  
A MR–/– mice or wildtype mice were injected i.v with 6 µg/g body weight aOVA. After 5 min, 
CD11c+ cells in kidney and rLN were analyzed for aOVA MFI (n=3). Background fluorescence 
intensity detected in DC from non-injected mice was substracted from the MFI values. 
B From MR-/- and wildtype mice DC were isolated from kidney, rLN and BM and stained 
intracellularly for MR.  
C CCR7–/– or wildtype mice were injected i.v with 8 µg/g body weight OVA-DQ. After 1 h, total 
rLN were analyzed for CD11c expression and antigen uptake. Results are representative for 2 
individual experiments. 
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7.2.3 Biased cross-presentation in the rLN towards filtrated antigen 
 
To investigate whether filtrated antigen was presented to T cells, mice were injected with 
OVA and CFSE-labeled transgenic OVA-specific CD8+ T cells (OT-I cells), which have been 
widely used for detecting cross-presentation of OVA (25). Indeed, OT-I cells proliferated 
more vigorously in rLNs than in cLNs in a dose dependent manner (Fig. 23 A, B). After 
injection of 10 µg OVA per g body-weight, the division index was 3 times higher in rLN than 
in cLN (Fig. 23 A, B), consequent with the difference found in the uptake of aOVA in these 
LNs (Fig. 20 A, B). Also higher aOVA doses were presented more efficiently in rLNs, 
whereas doses lower than 5 µg/g body weight did not cause significant T cell activation in any 
LN (Fig. 23 A, B). OT-I cell proliferation in the spleen was always higher than in rLNs (Fig. 
23 A, B), in harmony with the efficient OVA uptake by splenic DC (Fig. 15).  
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Figure 23. Biased cross-presentation in the rLN towards filtrated antigen  
A 2x106 CFSE-labeled OT I cells were injected into C57Bl/6 mice. 18 h later, different doses of 
OVA were i.v. injected. 48 hrs after OVA injection, the proliferation of OT I cells was analyzed in 
spleen, cutaneous and rLN. Histogram shows the proliferation profiles of CFSE+CD8+ cells. The 
numbers indicate the division index ± SD (n=3 mice) 
B Statistical analysis of Fig. 23 A. The ratio between the division indices in the spleen or in rLNs 
divided by that of the cLN was given as a quantitative parameter for the superiority of spleen and 
rLNs in proliferation of soluble antigen at different doses. 
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7.2.4 T cell activation by filtrated molecules leads to tolerance 
 
7.2.4.1 T cells activated by filtrated antigen in the rLN show a tolerized 
phenotype 
 
To investigate the fate of T cells activated by filtrated antigen, activation markers on OT-I 
cells proliferating in response to such antigen were examined. Expression of CD44 was 
increased, and CD62L was decreased when compared to naive OT-I cells (Fig. 24). However, 
these activation signs were much smaller than those displayed by OT-I cells proliferating in 
response to OVA in complete Freund’s adjuvant (OVA/CFA), which served as control for 
immunogenic priming (Fig. 24). In particular, these cells upregulated the high affinity IL-2 
receptor alpha chain, CD25, whereas those in the rLN showed levels hardly above those of 
naive OT-I cells (Fig. 24).  
 
 
Figure 24. T cells activated by filtrated antigen in rLN show a tolerized phenotype 
2x106 CFSE-labeled OT I cells were injected into C57Bl/6 mice. After 18 h, either 10µg/g body weight 
of OVA was injected i.v. or OVA-CFA s.c. 48 h later, expression of CD44, CD25, and CD62L on OT-I 
cells proliferating in response to these two antigen forms or in unprimed control mice were determined.  
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Consistent with this surface phenotype, OT-I cells; activated by filtrated antigen; after 
restimulation produced little IFNγ, and hardly any IL-2, whereas OT-I cells responding to 
OVA/CFA produced both cytokines in high amounts (Fig. 25 A, B).  In order to further 
characterize the tolerogenic phenotype it was determined whether the OT-I cells could develop 
OVA-specific cytotoxic effector function. Priming with soluble OVA cytotoxicity was evident 
neither in rLNs, nor in any other location (Fig. 26). In contrast, cytotoxicity was detected in 
the draining cLN of mice s.c. injected with OVA/CFA, and to a lower extent in other LN and 
in the spleen (Fig. 26), presumably due to recirculation of activated OT-I cells. 
 
 
 
Figure 25. T cells activated by filtrated antigen in rLN showed impaired production of cytokines 
A Intracellular IL-2 and IFNγ staining of CFSE-labeled OT-I cells proliferating in response to 
filtrated OVA or to OVA/CFA as described in Fig 24. 
B Quantitative analysis of Fig. 25 A, showing the proportions of cytokine-producing OT-I cells 
in different organs (3-4 mice per group) 
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Figure 26. T cells activated by filtrated 
antigen show no cytotoxicity 
Mice were injected with 1x104 naive OT I 
cells and after 18 h, with either 10 µg/g 
body weight of soluble OVA i.v. or of 
OVA-CFA s.c. 5 d later, target cells were 
injected and 4 h later specific in vivo 
cytotoxicity was determined in different 
organs (n=3 mice) 
 
 
 
7.2.4.2 T cells tolerized in the rLN are unable to participate in homeostatic 
proliferation presumably due to their deletion 
 
Finally, the life span of T cells activated by filtrated antigen was determined. To this end, OT-
I cells activated in the rLN of OVA-injected mice were transferred into RAG–/– secondary 
recipient mice, in order to subsequently determine their survival (experimental plan in Fig. 27 
A). However, transfer of OT-I cells separated from the other cells in rLNs was impossible, 
because the very small cell numbers in the tiny rLN (usually in case of OVA primed animals 
0.8-1.4 % of total living cells were OT-I cells) precluded all isolation or sorting attempts. To 
overcome this technical problem, we transferred total rLN cells pooled from several mice, and 
subsequently examined the proportion of OT-I cells within all transferred CD8+ T cells. As 
control for immunogenic priming, draining cLN cells from OT-I cell-injected mice primed s.c. 
with OVA/CFA were transferred. A further control for naive OT-I cells was necessary, 
because rLNs contained not only OT-I cells activated by filtrated antigen, but also non-
activated OT-I cells (Fig. 23, 24, 25) that presumably had not yet encountered OVA-
presenting DC after entering the node. To this end, rLN cells were transferred from mice 
injected with OT-I cells, but not with OVA.  
OT-I cells were more abundant in mice primed with soluble OVA or OVA/CFA than in 
unprimed animals (Fig. 23), consistent with their proliferation in these animals after priming 
in particular to OVA/CFA (Fig. 23). Two weeks after transfer into secondary recipients, the 
frequency of OT-I cells primed by filtrated antigen was reduced to the level of naive OT-I 
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cells (Fig. 27 B). In contrast, the frequency of OT-I cells activated by OVA/CFA had not 
declined (Fig. 27 B), indicating that immunogenically primed OT-I cells had been 
programmed to survive, as opposed to those primed by filtrated antigen. The loss of antigen 
specific OT-I cells was antigen specific, because the frequency of Vα2+ Vβ5– CD8+ cells, 
which were examined as examples for non-OVA-specific CD8+ T cells, was not significantly 
altered in any experimental group (unprimed 6.6±2.8, filtrated antigen 3.5±1.4, OVA/CFA 
3.3± 0.3 % of total CD8+ T cells, n=3, p>0.17 for all comparisons). Taken together, OT-I cells 
primed in response to filtrated soluble antigen not only showed a tolerized phenotype, but also 
lacked cytotoxic activity and showed a reduced life-span, indicating induction of cross-
tolerance. 
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Figure 27. T cells activated by filtrated antigen in rLNs are deleted 
A Experimental plan: 2x106 CFSE-labeled OT I cells were injected into C57Bl/6 mice. After 18 
hrs, mice were injected with either 10 µg/g of OVA i.v. or OVA-CFA s.c. After 48 h, single 
cell suspensions from the rLNs or the cLNs were transferred into RAG–/– secondary recipient 
mice. rLN cells were pooled from 6-8 first recipient mice. 12 d later, spleen and LN cells from 
RAG–/– mice were analyzed for the frequency of OT-I cells.  
B Proportions of Vα2+ Vβ5+ OT-I cells in all CD8+ cells before and after transfer into RAG–/– 
mice. (2 experiments using 2-3 mice per group). 
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7.2.5 Steady state migration of kDCs is not required for inducing T cell 
activation and tolerance induction towards filtrated antigen in rLN 
 
In spite of the fast cell-independent enrichment of filtrated antigen in the rLN, kidney DC also 
demonstrated remarkable uptake capacity towards molecules filtrated in the kidney. Therefore 
the question should be raised whether the CD8 T cell response; induced in rLN; was mediated 
by LN-resident DC or by kidney DC involved in steady-state migration. The latter possibility 
would involve that filtrated antigens are taken up in the kidney and transported to draining LN 
by kDCs. To distinguish between these two possibilities, proliferation of OT-I cells was 
examined in mice unilaterally nephrectomized after injection of OVA. Nephrectomy was 
carried out 90 min after antigen injection, because this time had been reported to suffice for 
clearing the murine plasma of a single bolus injection of filterable molecules (186). 
Importantly, during this time period no significant amount of antigen accumulation was found 
in the cLN (Fig. 28), indicating that antigen enriched in rLN predominantly derived from the 
kidney and not from the circulation. Indeed, OT-I cell proliferation was similar in the 
ipsilateral and contralateral rLN of nephrectomized mice, and in sham-operated animals (Fig. 
29 A, B), indicating that rapidly transported antigen was sufficient to drive T cell proliferation. 
Hypothetical DC-mediated steady-state antigen transport at later time points was not required.  
 
 
Figure 28. Presence of DQ-OVA 1 hr after 
injection into wildtype mice 
Wildtype mice were injected i. v. with 8µg/g body 
weight DQ-OVA. 1 hr after injection cLN and rLN 
were analyzed for CD11c expression and OVA 
uptake. Cells shown are PI negative. 
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Figure 29. Effect of steady state DC migration on the T cell response against filtrated antigen  
A Left nephrectomy (NX) was performed 90 min after injection of OVA. Division indices of 
proliferating OT-I cells were determined in the left and right rLN after left nephrectomy (NX), 
and in the left rLN of sham-operated animals. (n=6 mice per group, rLNs from 2 mice were 
pooled for analysis). 
B Same experimental setup as in Fig. 29 A, shown are the intracellular IL-2 and IFNγ content of 
OT-I cells proliferating in the left and right rLN and in the left rLN of sham-operated animals.  
C Quantitative analysis of Fig 29 B, showing the proportions of cytokine-producing OT-I cells (6 
mice per group, rLNs from 2 mice were pooled for analysis). 
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Furthermore, OT-I cells produced low cytokine amounts also when mice were unilaterally 
nephrectomized 90 min after OVA injection (Fig. 29 B, C). Thus, rapidly transported antigen 
presented by LN resident DC was sufficient for imprinting OT-I cells for defective cytokine 
production, demonstrating once more that hypothetical DC-mediated antigen transport at later 
time points was not required. 
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8. Discussion 
 
 
8.1 Part 1: The mannose receptor mediates uptake of soluble, but not of cell-
associated antigen for cross-presentation 
 
The MR is best known for its role as a scavenger receptor active in macrophages. A role in 
antigen presentation has been proposed by others based on its expression by human DC in 
vitro, and on its role in the uptake of mannosylated structures such as dextranes or horseradish 
peroxydase in a mannan-blockable fashion (95, 121, 187). Although, mannan and 
mannosylated proteins bind with high affinity to MR, they can also bind to other C-type lectin 
receptors such as DC-SIGN (127) that could also contribute to the antigen presentation 
observed in above studies. To circumwent the specificity concerns MR deficient mice were 
used to investigate the role of the MR in antigen presentation.  
The present study showed that the MR predominantly mediated the uptake of soluble OVA by 
DC in vivo. Concomitantly, in MR deficient mice the activation of naive CD8 T cells by 
soluble OVA was diminished. This was most likely due to reduced cross-presentation of 
OVA, because the absence of the MR did not affect the expression of costimulatory molecules 
on DC. Reduced recirculation of activated OT I cells was also ruled out as alternative 
explanation by showing that OT I cell activation was unaltered in MR–/– mice responding to 
cell-associated antigen. Also differences in the DC subtype composition of MR-deficient mice 
were unchanged, in particular the content of CD8α+ DC, which have been reported to mediate 
in vivo cross-presentation of soluble and cell associated OVA (37, 39). The MR was abundant 
in freshly isolated DC of the spleen, bone marrow and LN, despite one previous early report 
showing lack of MR expression (131). As opposed to the immunohistochemical detection of 
MR in that study (131), here a more sensitive method was used: intracellular staining and 
analysis by flow cytometry. This allowed the detection of low expression levels of the MR in 
DCs. Therefore the discrepancy to the previous study is most likely due to technical 
differences and limitations in detection sensitivity. Importantly, the MR was exclusively found 
in CD8α+ DC of the spleen, suggesting it may be used as a further marker for cross-presenting 
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APC in vivo besides CD8α (37) and DEC-205 (185). Only CD8α+ DC were capable of cross-
presntation of soluble antigen, although both CD8α+ and CD8α- DC were able to aquire 
antigen (39). These findings suggested that the cross-presentation ability is differentially 
regulated within the subsets. One hypothesis of the present study is that the receptor that 
mediates uptake of a given antigen may determine its intracellular routing and its presentation 
to T cells. This notion was verified by showing that the MR could target the antigen to the 
cross-presentation pathway. This mechanism may be complimentary to the recent finding that 
CD8α+ DC have higher expression of MHC I processing machinery compared to CD8α- ones 
(185).  
In contrast to soluble OVA, uptake of cell-associated OVA and the resulting activation of OT-
I cells were not impaired by the absence of the MR. The cell-associated antigen used in the 
present study was actively taken up by the bm1 cells, at least in part (Fig. 9). These cells 
before injection were UV irradiated in order to induce apoptosis. The efficient elimination of 
dying or death cells in vivo is crucial for tissue homeostasis. The surface molecules present on 
apoptotic cells and their receptors expressed by phagocytes form the phagocytic synapse (91). 
Many receptors have been considered to be involved in the formation of such synapse such as 
complement-, scavenger-, PS receptor and different integrins (3, 91). The role of some of these 
receptors was investigated in gene deficient animals such as CD36 knockout mice, but no 
essential role in the clearance of apoptotic cells has been observed yet (90). This has been 
explained by functional redundancy between these receptors. The present study excluded the 
MR as one such receptor. Thus, the mechanisms mediating antigen uptake for classical cross-
priming as described by Bevan (36) remain to be resolved. 
Taken together, the present study provided formal in vivo evidence that a particular uptake 
receptor, here the MR, can specifically introduce antigen (soluble OVA) into the cross-
presentation pathway.  
These findings suggest that in vivo targeting of the MR may be useful for introducing 
extracellular antigen into the MHC-class I-restricted antigen presentation pathway. Targeting 
of a related lectin, DEC205, has been shown to result in tolerogenic CD4 and CD8 T cell 
activation (100). It will be interesting to investigate whether antigen uptake by the MR would 
result in immunogenic or tolerogenic CTL priming, or in both, depending on the absence or 
presence of inflammatory stimuli. Finally, paralell work on BM-DC in vitro carried out by Dr. 
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Sven Burgdorf (182) in Prof. Kurts`s laboratory has shown that in these cells uptake and cross-
presentation of soluble OVA was completely abrogated in MR deficient DCs. Using this in 
vitro system may allow to understand which intracellular mechanisms are involved and how 
MR target the cross-presentation pathway. 
 
 
8.1.1 Summarized features of the cross-presenting APC 
 
The present study provides evidences that an antigen uptake receptor, the MR, targets antigen 
specifically into the cross-presentation pathway. These results extend the characteristic 
features of the cross-presenting APC in the spleen. These properties are summarized in Table 
2. 
 
Cross-presentation +++ - (36) 
CD8α + - 16, 37, 39) 
DEC-205 + - 
(13, 100, 
185) 
DCIR2 - + (185) 
MR + - (182) 
 
Table 2. Summary of the surface markers, which are characteristic of the cross-
presenting DCs in spleen 
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8.2 Part 2: Lymph node-resident dendritic cells induce T cell cross-tolerance 
against tissue-derived antigen 
 
Systemic injection of soluble antigen devoid of inflammatory stimuli has been widely used to 
study mechanisms of T and B cell tolerance (178, 180, 181). This system is thought to mimic 
presentation of innocuous self-serum proteins and orally administered antigen, against which 
immunity is not required, or may even be harmful. It is generally assumed that such tolerance 
is induced in the spleen, which presents soluble antigens to T cells particularly well (75, 143, 
174, 188). However, splenectomy usually does not result in auto-immunity against otherwise 
ignored soluble antigens, suggesting that further sites may exist where tolerance can be 
induced. One possible such site may be the kidney-rLN system because of the physiologic 
filtration of circulating molecules below albumin size in kidney glomeruli. Liquid reabsorption 
from the glomerular ultrafiltrate causes enrichment of such molecules in the kidney tubular 
system (27). Unlike metabolic waste products, filterable proteins are not excreted with the 
urine, but instead are reabsorbed by tubular epithelial cells. Dong et al. recently reported that 
filterable dextran molecules were taken up also by kDC (23). In the present study, 
simultaneous injection of small and large fluorescent molecules allowed demonstrating that 
their uptake from the tubular filtrate was far more efficient than that from the circulation. 
Furthermore, it revealed selective enrichment of filterable protein antigen in kDC and rLN 
DC. It has been reported that tubular cells of the kidney regularly sense filtrated proteins, such 
as albumin and growth factors and that they can respond with secretion of chemokines that 
might affect renal diseases (35). What consequences filtrated proteins exert on DCs and what 
role they play in renal diseases remained to be elucidated. This open question was addressed in 
the present study by showing that their enrichment in the rLN resulted in efficient activation of 
naive CD8+ T cells at concentrations too low for priming in any other LN. Also the spleen 
enriched soluble antigen, and even more efficiently so than rLNs. This observation was 
consistent with the previous identification of a splenic conduit system that efficiently targeted 
soluble small molecules to the T cell/DC areas (143). Also LNs (141) and the thymus (142) 
contain conduit systems. Such a system may also have conveyed filtrated antigen arriving with 
the lymph flow towards resident DC within rLNs. In addition to such anatomical structures, 
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the present study reveals that concentration of filterable antigen in the kidney acts as a 
functional mechanism for improving presentation of soluble antigen.  
Presentation of filtrated antigen induced CD8+ T cell cross-tolerance, as evidenced by low 
activation markers, such as CD25. The lack of upregulation of this receptor is often considered 
a phenotypic feature of tolerized T cells for example after activation by autoantigen (174). 
Tolerance induction was further supported by the lack of significant cytokine production, for 
example of IFN-γ and IL-2, and by the absence of cytotoxic activity. Finally, the life span of 
the activated OT-I cells was determined. Demonstrating this latter point was technically 
demanding, because rLNs contained not only activated, but also naive OT-I cells that had not 
yet been tolerized. The extremely low cell numbers in this node precluded separation of naïve 
and activated OT-I cells for determining their individual life spans. Nevertheless, transfer of 
unseparated OT-I cells to Rag-/- recipients allowed demonstrating their decline to the level 
observed after transfer of naïve OT-I cells. Suggesting that OT-I cells primed in renal LN with 
filtrated soluble antigen were unable to participate in homeostatic proliferation after transfer 
into immunodeficient recipients. This suggested that activated OT-I cells had been deleted, 
while the naïve ones survived. Induction of anergy as an alternative explanation to deletion is 
unlikely, because others showed that transfer into RAG–/– mice rescued anergic T cells, and 
enabled vigorous homeostatic proliferation (189). Thus, the observed decline of OT-I cells 
activated by filtrated antigen most likely indicates their deletion as most likely explanation. 
Thus, the rLN is a unique site where deletional T cell-tolerance against filterable antigen is 
induced. 
The selectivity of enrichment for filterable molecules in kDC and in rLN DC allowed studying 
how soluble antigen was transported from the kidney to the rLN. Strikingly, several lines of 
independent evidence indicated that this transport did not occur via steady-state DC migration. 
First, enrichment of filtrated antigen was detectable already 90 sec after antigen injection. 
Moreover, 5 min after injection, 40-50x103 of DC carrying filtrated antigen were present in the 
left kidney, whereas the left rLN contained 2-3x103 DC (Fig. 21 B). If all these rLN DC had 
arrived from the kidney within this short time-span, then more than 500x103 DC would 
migrate per day. In this case, kDC would turn over more than 10 times and rLN DC more than 
200 times per day, which is clearly incompatible with reports by others showing DC half-lifes 
of 1.5-2.9 days in the spleen (190) and >2 weeks in the kidney (23). These estimations of DC 
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turnover, together with the remarkably rapid kinetics of antigen relocation are not compatible 
with low-level steady-state DC migration over longer time spans.  
The observed phenotypical differences between DC carrying filtrated antigen in the kidney 
and in the rLN provide the second argument against DC migration. Downregulation of CD11c 
and upregulation of CD8α+ in such short time appears unlikely. Besides, CD8α+ is considered 
a lineage marker that is not expressed de novo on conventional DC (16, 18, 20), such as those 
residing in the kidney (21). The absence of CD8α+ DC from the kidney demonstrated that the 
few CD8α+ DC carrying filtrated antigen in the rLN couldn’t have immigrated from this 
organ. Third, most rLN DC rapidly took up large antigen amounts via the MR. Also these DC 
could not be kidney-derived, because this organ contained no such DC either. Fourth, the rapid 
accumulation of filtrated OVA in rLN DC was independent of CCR7, which is required for 
DC trafficking (8, 153, 154) to draining LNs and which is expressed by kDC (26). These four 
findings together can be explained only by cell-independent antigen transport to rLNs and 
subsequent uptake by LN-resident DC, which then induced cross-tolerance. 
Cell-independent antigen transport from peripheral tissues to draining LNs differs from 
previously described mechanisms of peripheral T cell tolerance via steady-state migratory DC 
(8, 17, 45). Previous studies relied on various approaches to label migratory DC, for example 
local labeling by FITC-painting, injection of fluorochromes or latex beads, or of labeled DC 
(140). It is difficult in any of these approaches to exclude that the labeling process itself leads 
to DC maturation and triggers migration. The approach of i.v. injection of tracers in this work 
bona fide allowed physiologic labeling of DC and reproducibly did not result in any detectable 
maturation. Under these conditions, tolerance was induced without DC migration. While these 
finings do not exclude DC-mediated antigen transport to rLNs at later times points, but 
nephrectomy experiments in the present study demonstrated (Fig. 29) that such hypothetical 
steady state migration was not required for T cell activation and tolerization in this system.  
Recently, stromal LN cells that expressed the Aire gene as well as peripheral self-antigens 
have been shown to tolerize autoreactive CD8+ T cells (179). DC-independent relocation of 
antigen to LN-resident DC indicates a further mechanism of tolerance induction in secondary 
lymphatics. Others have previously shown antigen transfer to LN-resident DC from migratory 
DC (17). This antigen transport mechanism has been documented in models of herpes virus 
infection in the skin and in the lung resulted in immunogenic T cell activation (57, 151). Apart 
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from the organ studied, this system differs from above findings by the presence of an 
infectious agent that could mature DC and induce their migration. In contrast, when innocuous 
antigen was injected into the skin, it reached the LN through lymph vessels before skin-
derived DC had immigrated (148-150). Also the kidney is connected with its draining LN by 
lymph vessels, as demonstrated by cannulating experiments in sheep (191). Cannulation of the 
tiny lymph vessels of mice, however, has not been achieved yet. At least in rats, renal 
lymphatic vessels have been microscopically observed, albeit only after ureteral obstruction, 
when lymph vessels were blocked and enlarged by lymphatic fluid (192). In human renal 
biopsies, lymphatic vessels were large enough to be microscopically detectable in healthy 
organs (193). Such vessels may anatomically explain how filtrated antigen was relocated in a 
cell-independent manner from the kidney to its LN, even though above study does not provide 
direct evidence for lymph vessel mediated antigen transport. 
Nevertheless, these results demonstrate that DC-independent relocation of innocuous 
circulating antigen from the kidney to the rLN and local uptake by resident DC can result in T 
cell tolerance. This mechanism may contribute to prevent unwanted immunity against self-
serum proteins or innocuous orally administered antigen. 
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8.2.1 Model of handling of filtrated molecules in the kidney-renal LN system 
 
Taken together the above results support the following model (Fig. 30): molecules below of 
albumin size are concentrated in the kidney due to their filtration in the glomeruli. These 
filtrated molecules are transported rapidly via cell-independent mechanism to the draining 
renal LN. These molecules are endocytosed by LN resident DCs. Presentation of filtrated and 
accumulated antigen in renal LN results in a biased cross-presentation, which in turn causes 
tolerogenic CD8 T cell activation. Therefore, the kidney–renal LN system could participate in 
elimination of autoreactive CD8 T cells against small, filterable self-proteins such as serum 
proteins or food-antigens. 
 
 
Figure 30. Model of handling filtrated molecules by the kidney-renal LN system 
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The Mannose Receptor Mediates Uptake of Soluble but Not of
Cell-Associated Antigen for Cross-Presentation1
Sven Burgdorf,2 Veronika Lukacs-Kornek,2 and Christian Kurts3
The mannose receptor (MR) has been implicated in the recognition and clearance of microorganisms and serum glycoproteins. Its
endocytic function has been studied extensively using macrophages, although it is expressed by a variety of cell types, including
dendritic cells (DC). In this study, we investigated its role in Ag presentation by DC using MR/ mice. Uptake of the model Ag,
soluble OVA, by bone marrow-derived DC and in vitro activation of OVA-specific CD8 T cells (OT-I cells) strictly depended on
the MR. In vivo, MR deficiency impaired endocytosis of soluble OVA by DC and concomitant OT-I cell activation. No alterations
in the DC subtype composition in MR/ mice were accountable. Uptake of cell-associated OVA was unaffected by MR deficiency,
resulting in unchanged activation of OT-I cells. These findings demonstrate that DC use the MR for endocytosis of a particular
Ag type intended for cross-presentation. The Journal of Immunology, 2006, 176: 6770–6776.
T he mannose receptor (MR)4 is a 180-kDa transmembraneC-type lectin that functions as an endocytic receptor. Ithas been implicated in the recognition of various micro-
organisms (1). Furthermore, the MR plays a homeostatic role in
the clearance of glycoproteins, such as -glucuronidase and pro-
collagen, which are up-regulated in the blood serum during in-
flammation (2). The MR consists of an N-terminal cysteine-rich
domain, a fibronectin type II repeat domain, eight carbohydrate
recognition domains (CRD), a transmembrane domain, and a short
intracellular region (3). The cysteine-rich region mediates binding
to sulfated sugar moieties, whereas the CRD bind glycoproteins
bearing (for instance) terminal mannose, fucose, and, with a lower
affinity, glucose residues (4). Most studies addressing the function
of the MR have used macrophages (5), which use it for uptake of
mannosylated structures such as dextrans (1). In addition to these
cells, the MR has also been detected in liver endothelial cells,
dermal microvascular endothelial cells, monocytes, Langerhans
cells, and dendritic cells (DC) (6).
DC play a central role in the induction of adaptive immune
responses (7). After capturing and internalizing Ag in peripheral
organs, they migrate toward the draining lymph nodes, where they
can activate naive T cells. For activation of CD8 T cells, captured
extracellular Ag are presented on MHC class I molecules (8)—a
process termed cross-presentation—which contributes to the in-
duction of cytotoxicity against many viruses and tumors (9). The
murine DC subpopulation expressing the CD8 homodimer has
been shown to be particularly relevant for cross-presentation of
foreign Ag (10) and of self Ag under homeostatic conditions (11,
12). In the presence of inflammatory stimuli, also CD8-deficient
DC were able to cross-present (13, 14).
Several receptors mediating Ag uptake in DC have been iden-
tified, such as Fc-receptors, DC-SIGN and DEC205. A role of the
MR in Ag uptake and presentation by DC has been proposed based
on the finding that mannosylated proteins are presented more ef-
ficiently than nonmannosylated ones (15, 16). It is unclear, how-
ever, whether this uptake was due to the MR, because DC express
other receptors, such as DC-SIGN, with affinity for mannosylated
proteins (6, 17). For the same reason, mannan, a polymer of man-
nose, which competitively blocks endocytosis of mannose-rich
structures, cannot be considered a specific inhibitor of the MR. To
overcome these limitations, we have used MR/ mice to eluci-
date the role of the MR in the uptake and presentation of soluble
vs cell-associated OVA.
Materials and Methods
Mice
MR/ mice on a C57BL/6 (B6) background were generated and provided
by Dr. M. C. Nussenzweig (Rockefeller University, New York, NY) (2).
B6 mice bearing the Kb mutant bm1 (bm1 mice) and OT-I Rag-1/ mice
on a B6 background were provided by Dr. W. R. Heath (Walter and Eliza
Hall Institute of Medical Research, Melbourne, Australia) (18). For all
experiments, mice between 8 and 16 wk of age bred under specific patho-
gen-free conditions were used in accordance with local animal experimen-
tation guidelines.
Abs and reagents
All mAb used were purchased from BD Biosciences, except anti-MR Ab
(Serotec) and SF1, which were purified from hybridoma supernatant
(American Type Culture Collection) and used after conjugation with al-
exa488. All reagents, if not specified otherwise, were obtained from
Sigma-Aldrich.
Generation of bone marrow-derived dendritic cells (BMDC)
BMDC were generated using GM-CSF as described previously (19). At
day 7, CD11c cells isolated by magnetic separation with the autoMACS
system (Miltenyi Biotec) were used for all in vitro experiments. Purity of
CD11c cells was typically higher than 98%.
Preparation of fluorescent soluble and cell-associated OVA
Soluble OVA was conjugated to a fluorochrome using an alexa647 labeling
kit (Invitrogen Life Technologies) according to the manufacturer’s guide-
lines. The labeling procedure involved gel filtration as a final step for
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removal of low molecular mass molecules such as unbound fluorochrome.
For cell-associated OVA, splenocytes from bm1 mice (2  108 cells/ml)
were incubated with 10 mg/ml OVA-FITC for 10 min at 37°C, UV-irra-
diated with 15 mJ for 5 min, and washed extensively. For cell culture
experiments, 106 splenocytes were coincubated with 4  105 BMDC for
18 h.
Cross-presentation assays
OT-I cells were isolated from OT-I rag/ mice as previously described
(18) and further purified by a nanobead-based CD8 T cell isolation kit
(Miltenyi Biotec). Purity was typically higher than 96% of viable cells;
contaminating CD11c cells were typically rarer than 0.2%, NK1.1 cells
rarer than 0.03%, and CD4 cells below 1%. For presentation of soluble
OVA, 4  105 BMDC were stimulated with 10 g/ml LPS for 2 h and
incubated with 500 g/ml OVA or 20 nM SIINFEKL (OVA peptide).
After another 3 h, cells were washed, fixed with 0.008% glutaraldehyde for
3 min, and coincubated with 2  105 OT-I cells. IL-2 concentrations were
determined after 18 h by ELISA. For the analysis of cell-associated Ag,
bm1 splenocytes were coated with OVA as described above. Splenocytes
(106) were coincubated with 4  105 BMDC and 2  105 OT-I cells. IL-2
concentrations in the supernatant were determined by ELISA after 40 h.
Isolation of DC from experimental animals
Cells were isolated from spleen and cutaneous lymph node (cLN) as de-
scribed before (12). For the preparations from bone marrow, cells were
collected by flushing femurs and tibias with PBS. CD11c cells from all
organs were enriched by magnetic separation using MS25 columns (Milte-
nyi Biotec). Purity was typically higher than 85%.
Flow cytometry, data analysis, and statistics
Flow cytometry was performed on an LSR (BD Biosciences). Dead cells
were excluded by Hoechst-33342 dye. Data were analyzed using Flow-Jo
software (Tristar), including calculation of division indices, which indicate
the average number of cell divisions. Statistical analysis was done using
Excel (Microsoft). All experiments reported here have been reproduced at
least twice.
Results
The MR is essential for uptake of soluble but not of
cell-associated OVA by BMDC
When we studied uptake of OVA in BMDC, we noticed that only
some of the CD11c cells took up this model Ag in vitro (Fig. 1,
A and B), as others have noted recently (20). We reasoned that this
might be explained by selective expression of an endocytic recep-
tor that mediated uptake of OVA. In support of this hypothesis, we
observed a close correlation between the uptake of OVA and the
extent of MR expression (Fig. 1A). To investigate whether this
association was due to a functional role of the MR in Ag uptake,
we preincubated the DC with mannan, which competitively inhib-
its MR-mediated endocytosis (21). This agent blocked the uptake
of OVA completely (Fig. 1B). To exclude an influence of other
receptors with affinity to mannan, we performed this experiment
also with BMDC from MR/ mice (2). These cells did not show
any uptake (Fig. 1, B and C), indicating that the MR was indis-
pensable for endocytosis of soluble OVA by BMDC in vitro. Re-
markably, under these experimental conditions, no other receptor
appeared to compensate even partially for the absence of the MR.
To exclude the possibility that BMDC generated from MR/
mice differed from those from wild-type mice in terms of subtype
composition or maturation status, we phenotypically characterized
these DC. Consistent with reports from others (22, 23), BMDC
expressed CD11b but not CD8 (Fig. 1D). CD11c and CD11b
expression was identical in both BMDC populations (Fig. 1D), as
was constitutive and LPS-induced expression of costimulatory
molecules (Fig. 1E), suggesting equivalent states of maturation.
Next, we investigated whether the MR was important also for
the uptake of cell-associated OVA, using splenocytes loaded with
fluorochrome-labeled OVA (Fig. 2A). To demonstrate intracellular
uptake, loading was performed at 4°C and at 37°C, because intra-
cellular uptake is energy-dependent, as opposed to extracellular
coating. Indeed, uptake at 37°C was significantly higher than at
4°C, suggesting that some of the Ag was transported into the
spleen cells. We then induced apoptosis by UV irradiation and
cocultured these cells with BMDC from MR/ mice or controls.
After 18 h, the uptake of cell-associated OVA by wild-type and
MR/ cells was indistinguishable (Fig. 2B), indicating that re-
ceptors other than the MR had mediated endocytosis of
cell-associated OVA.
The MR is required for cross-presentation of soluble but not of
cell-associated OVA in vitro
The requirement of the MR for OVA uptake suggested a role in Ag
presentation. To address this hypothesis, we studied cross-presen-
tation of OVA in coculture experiments with BMDC prepared
from B6 or MR/ donor mice and OVA-specific CD8 T cells
isolated from transgenic OT-I mice. Their activation was moni-
tored by measuring IL-2 release into the culture supernatant. This
release correlated with the Ag amount in a dose-dependent fashion
(Fig. 3A). To ensure that OT-I cell activation was in fact due to
cross-presentation, and not to coating of the BMDC with peptide
fragments present in the OVA solution, we performed incubation
with soluble OVA in the presence of the proteasome inhibitor
MG132, which inhibits intracellular generation of peptides for
loading onto MHC class I molecules (24). This inhibitor prevented
IL-2 release nearly completely (Fig. 3A), indicating that OT-I cells
were indeed activated by OVA peptides generated intracellularly.
MG132 did not affect OT-I cell activation by BMDC coated with
the OVA peptide SIINFEKL, which is recognized by OT-I cells,
demonstrating that in this experimental setting, the ability of OT-I
cells to produce IL-2 was not compromised (Fig. 3A).
When BMDC from MR/ mice were used, they induced se-
verely reduced IL-2 production by OT-I cells as compared with
wild-type cells (Fig. 3B), demonstrating that MR-mediated uptake
of soluble OVA could provide Ag for cross-presentation. MR-
deficient DC externally loaded with SIINFEKL activated OT-I
cells equally well as DC from wild-type mice (Fig. 3B), indicating
that BMDC from MR/ mice were not compromised in their
general ability to activate T cells. Thus, the MR mediated not only
uptake of OVA, but also the resulting activation of OT-I cells.
Because the uptake of cell-associated OVA was not reduced in
MR-deficient DC, we tested whether OT-I cell activation remained
operative as well. To this end, we loaded splenocytes from bm1
mice with OVA. These mice bear a mutant H2-Kb protein that
cannot present OVA to OT-I cells (18). After coating with OVA,
apoptosis was induced by UV irradiation. These cells were then
cocultured with wild-type and MR-deficient BMDC and OT-I
cells. No differences in T cell activation between the two DC types
could be observed in vitro (Fig. 3C), indicating that the MR not
only was dispensable for the uptake but also for intracellular pro-
cessing of cell-associated OVA for cross-presentation.
The MR contributes to in vivo uptake of soluble but not of
cell-associated OVA by DC
Next, we decided to investigate the in vivo role of the MR in Ag
uptake. To this end, we injected fluorochrome-labeled soluble
OVA into B6 mice. Consistent with our in vitro findings, a close
correlation between the uptake of soluble OVA and the expression
of the MR in DC was found (Fig. 4, A and B). DC from MR/
mice showed significant but incomplete reduction of uptake of
soluble OVA (Fig. 4, C and D). This was most evident in the
spleen and in the bone marrow, which have been described as
locations in which cross-presentation takes place (8, 25). In the
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FIGURE 1. The MR is essential for uptake of soluble OVA by BMDC. A, CD11c BMDC generated from B6 mice were incubated with alexa647-
conjugated OVA, stained for expression of the MR, and analyzed by flow cytometry. B, CD11c BMDC from C57/BL6 mice were treated for 30 min with
3 mg/ml mannan and then cocultured for 10 min at 37°C with 10 g/ml alexa647-OVA. Histograms show the uptake profiles of fluorescent Ag by
mannan-treated and untreated DC, and by BMDC from MR/ mice. Numbers indicate the MFI  SD; the proportions of the CD11c cells that had taken
up Ag are given above the histogram area indicators. C, Immunofluorescence images visualizing uptake of alexa647-OVA by BMDC. D, BMDC were
prepared from MR/ and wild-type mice and stained for expression of the subtype markers CD11c, CD11b, and CD8 (solid lines) or control (gray areas).
E, BMDC from MR/ and wild-type mice were stained for expression of the maturation markers CD80, CD86, CD40, and MHC class II following
stimulation for 24 h with 10 g/ml LPS (solid lines) or no stimulation (dashed lines).
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cLN, only moderate uptake was observed, which was further re-
duced in MR/ mice, albeit not significantly (Fig. 4, C and D).
This reduction was not due to changes of the DC subpopulations
present in MR/ mice, because these were indistinguishable from
those in wild-type mice (Fig. 4E). These findings demonstrated
that the MR was involved also in the in vivo uptake of soluble
OVA, but it was not essential, as opposed to its role in vitro.
Indeed, in wild-type mice we found some DC that had taken up
OVA but did not express the MR (Fig. 4B). The mechanisms that
partially compensated for the absence of the MR in vivo remain to
be identified.
Next, we examined the effect of the MR on the in vivo uptake
of cell-associated OVA by injection of UV-irradiated bm1 spleno-
cytes loaded with FITC-labeled OVA into MR/ mice and con-
trols. DC from the spleen and from the bone marrow of C57/BL6
mice showed significant uptake (Fig. 5, A and B). The cLN showed
only marginal uptake of cell-associated Ag, consistent with reports
by others (26). In MR/ mice, uptake was unaltered (Fig. 5, A
and B), implying that cell-associated Ag had been internalized by
mechanisms other than MR-mediated endocytosis.
The MR mediates cross-presentation of soluble but not of
cell-associated OVA in vivo
To assess the in vivo role of the MR for CD8 T cell activation by
cross-presentation, we injected CFSE-labeled OT-I transgenic T
cells into wild-type or MR-deficient recipient mice. After priming
with soluble OVA, we analyzed the proliferation of OT-I cells in
spleen, bone marrow, and cLN. In MR/ mice, proliferation of
these T cells was substantially reduced (Fig. 6A). Also, CD69 ex-
pression on OT-I cells was substantially diminished on day 1 in all
organs tested in MR/ mice (data not shown), demonstrating that
the diminished proliferation of OT-I cells was due to decreased
activation at the priming site, rather than to reduced recirculation
of OT-I cells activated elsewhere.
Finally, we examined the in vivo role of the MR in the presen-
tation of cell-associated OVA. Wild-type and MR/ mice were
injected with OT-I cells and primed with OVA-coated, UV-irra-
diated bm1 splenocytes. Proliferation of OT-I cells in the spleen
and in the bone marrow was not reduced in MR/ mice (Fig. 6B).
Moreover, no alterations in up-regulation of CD69 in the activated
T cells were observed (data not shown). Consistent with the mar-
ginal Ag uptake in the cLN, no proliferation of OT-I cells was
observed in this location (Fig. 6B). Thus, mechanisms other than
MR-mediated Ag uptake were responsible for CD8 T cell activa-
tion by cross-presentation of cell-associated Ag.
Discussion
The molecular mechanisms that mediate Ag uptake for cross-pre-
sentation are unresolved. The present study is the first to identify
a receptor involved in this process, by demonstrating that Ag en-
docytosed via the MR gained access to the cross-presentation path-
way. We showed that the MR was important for the uptake of
FIGURE 2. The MR is dispensable for uptake of cell-associated OVA
by BMDC. A, UV-irradiated splenocytes from bm1 mice were incubated
for 10 min at 4°C or 37°C with FITC-labeled OVA, and then analyzed for
uptake of fluorescent soluble Ag. B, UV-irradiated bm1 splenocytes loaded
with FITC-OVA at 37°C were cocultured with BMDC from wild-type or
MR/ mice. After 18 h, DC were analyzed for uptake of fluorescent
cell-associated Ag. Apoptotic bm1 splenocytes were excluded from anal-
ysis by forward scatter/side scatter gating or gating for Kb cells revealed
by staining with SF1 Ab. Numbers indicate the MFI  SD. The propor-
tions of the CD11c cells that had taken up Ag are given above the his-
togram area indicator.
FIGURE 3. The MR is essential for cross-presentation of soluble but
not of cell-associated OVA by BMDC to CD8 T cells. A, To establish an
in vitro system for CD8 T cell activation by cross-presentation, various
concentrations of soluble OVA or of the OVA peptide SIINFEKL were
coincubated for 2 h with BMDC from B6 mice in the absence (f) or
presence () of the proteasome inhibitor MG132. DC were then washed,
fixed, and cocultured with OT-I cells. After 18 h, IL-2 concentrations in the
culture supernatants were determined by ELISA. B, BMDC from wild-type
(f) or MR/ () B6 mice were incubated with 1 mg/ml OVA or 200 nM
SIINFEKL. After an additional 3 h, cells were fixed and naive OT-I cells
were added. IL-2 concentrations in the culture supernatants were deter-
mined at 18 h after addition of OT-I cells. C, Splenocytes from bm1 mice
were incubated with OVA, UV irradiated, and then cocultured with BMDC
from wild-type or MR/ mice and OT-I cells. After 40 h, IL-2 concen-
trations were determined.
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soluble OVA by DC in vivo, and that it was even essential for
BMDC in vitro. Concomitantly, the activation of naive CD8 T
cells by soluble OVA was diminished and in fact abrogated when
BMDC were used. This was most likely due to reduced cross-
presentation of OVA, because the absence of the MR did not affect
expression of costimulatory molecules. Furthermore, MR-deficient
DC loaded with OVA peptide induced a T cell response equal to
that induced by wild-type DC, implying that the costimulatory
signals provided must have been similar. Also, differences in the
DC subtype composition of MR-deficient mice were unchanged, in
particular the content of CD8 DC, which have been reported to
mediate in vivo cross-presentation of soluble and cell associated
OVA (10, 14).
As opposed to the clear-cut in vitro situation, uptake and cross-
presentation of soluble OVA in vivo was not completely abolished
in MR/ mice, yet it was significantly reduced. This may indicate
that BMDC do not mimic all mechanisms involved in Ag uptake
by DC in vivo. These mechanisms may involve the generation of
OVA peptides by endogenous proteases, or Ag uptake by addi-
tional cellular receptors, such as the lectins DC-SIGN and
DEC205, whose expression might differ between BMDC and DC
in living animals (17, 27). This may be the case for CD8 DC
that were shown to mediate cross-presentation in vivo (10, 14),
because these are known to be absent from BMDC generated by
standard methodology (22).
Uptake of cell-associated OVA and the resulting activation of
FIGURE 5. The MR is dispensable for in vivo uptake of cell-associated OVA. A, FITC-OVA-loaded bm1 cells (20  106) were UV-irradiated and
injected i.v. into wild-type and MR-deficient B6 mice. After 12 h, DC were isolated from spleen, bone marrow, and cLN, and the proportion of alexa647
cells in the viable CD11c cells was determined (n  3 or 4 mice). B, MFI  SD of the cells from A.
FIGURE 4. The MR predominantly mediates in vivo uptake of soluble OVA. A, Gating scheme used for analysis of Ag uptake by splenic DC. B, B6
mice were i.v. injected with alexa647-conjugated OVA (5 g/g body weight). After 45 min, single-cell suspensions from the spleen were stained for CD11c
and MR expression, and analyzed using the gate shown in A. C, Wild-type and MR-deficient C57/BL6 mice were i.v. injected with 5 g/g body weight
alexa647-conjugated OVA. After 45 min, DC were isolated from spleen, bone marrow, and cLN, and analyzed by flow cytometry. Numbers give the
proportions of alexa647 cells  SD within the viable CD11c cells (n  3 or 4 mice). D, MFI  SD of the cells from C. E, Alexa647 splenic CD11c
cells were stained for expression of the DC subtype markers CD11b and CD8, and analyzed by flow cytometry.
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OT-I cells were not impaired by the absence of the MR, either in
vivo or in vitro. The cell-associated Ag used in the present study
was located intracellularly, at least in part. Such Ag may be avail-
able for endocytosis by one or several distinct receptors. Reports
implicating CD36 in uptake of Ag borne by apoptotic cells are
controversial (28). Thus, the mechanisms mediating Ag uptake for
classical cross-priming, as described by Bevan (8), remain to be
resolved. Nevertheless, our findings demonstrated that additional
pathways exist for cross-presentation of Ag carried by microor-
ganisms, or of viral Ag within infected host cells.
The MR is mostly known for its role as a scavenger receptor of
macrophages. A role in Ag presentation has been proposed by
others based on its expression by DC and on its role in the uptake
of mannosylated structures such as dextrans or horseradish perox-
idase in a mannan-blockable fashion into cellular compartments
that contained MHC class II molecules (21). Such uptake could
result in stimulation of CD4 T cell clones in vitro (16), suggesting
a role for the MR in adaptive immunity. The findings reported here
support such a role by demonstrating MR-mediated activation of
naive CD8 T cells, and by providing evidence for in vivo relevance
of such activation. Furthermore, the use of MR/ mice in the
present study precluded the specificity concerns that apply to man-
nan blockade of the MR (6).
Our findings suggest that targeting of the MR may be useful for
introducing extracellular Ag into the MHC class I-restricted Ag
presentation pathway. Targeting of a related lectin, DEC205, has
been shown to result in tolerogenic CD4 and CD8 T cell activation
(27). It will be interesting to investigate whether Ag uptake by the
MR would result in immunogenic or tolerogenic CTL priming, or
both, depending on the absence or presence of inflammatory stim-
uli. Finally, the indispensability of the MR for uptake of soluble
OVA by BMDC may allow further in vitro dissection of intracel-
lular mechanisms governing cross-presentation.
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